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ABSTRACT 
The possible relationship among urinary dopamine levels, circulating 
dopamine levels, kidney dopamine levels and arterial blood pressure was 
studied in hypertensive rats and dogs. The role of the kidney in the for-
mation of dopamine from dihydroxyphenylalanine (DOPA) was also investigated 
in cats. 
Hypertension was produced by right renal nephrectomy followed in two 
weeks by contralateral renal artery compression. 
The blood pressure of both the rats and dogs showed a sharp increase 
the first week following the second operation and remained elevated for 
the duration of the study. Individual pressures as high as 205 mm Hg were 
encountered. 
Dopamine was extracted from urine by absorption onto alumina, converted 
to its trihydroxyindole derivative and measured fluorimetrically. Tissue 
and blood samples were for the most part homogenized in trichloroacetic 
acid, then passed through alumina columns. Dopamine was separated from 
DOPA by passing trichloroacetic acid extracts through columns of sodium 
Dowex 50W-X8 to extract dopamine, then through alumina columns to extract 
DOPA. 
Urinary dopamine levels were reported as micrograms per liter (pg/l), 
micrograms per 24 hours C,ug/24h) and micrograms per killogram per 24 hours 
(pg/kg/24h). In comparisons with a control group, the dopamine levels 
(pg/l) were significantly lower in the hypertensive group on several 
occasions, however dopamine levels expressed as vg/24h or pg/kg/24h 
differed only on two occasions; once prior to any operational procedures 
and then the first week following renal artery compression. A diuresis was 
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observed in the hypertensive animals which could account f or the decrease 
in urinary dopamine concentration (pg/l) which was obtained. Over the 
duration of the rat study, mean dopamine levels (pg/l) remained relatively 
constant and varied between 168 and 418 pg/l, paired mean dopamine levels 
(pg/24h) showed a tendency to rise and varied between 4.61 and 10.80 pg/24h 
and mean dopamine levels (pg/kg/24h) showed a slight tendency to decrease, 
ranging from 11.51 to 18.53 pg/kg/24h. 
Correlation and regression analyses for the dependency of arterial 
blood pressure on urinary dopamine levels (pg/l, pg/24h and µg/kg/24h) . did 
not detect any statistically significant relationships. No significant 
relationship was established between ' dopamine levels (pg/kg/24h) and 
weight (gm). 
Dopamine could not be detected in the blood of hypertensive rats or 
dogs, or in the ischemic kidneys of hypertensive rats. 
The infusion of DOPA into cats with and without functional renal 
tissue produced similar tissue dopamine levels in the liver, heart and 
spleen, However, renal arterio-venous differences showed that some DOPA 
was decarboxylated to dopamine in the kidney. 
No evidence was obtained in the study which implicated dopamine in 
the hypertensive process and no relationship between arterial blood pressure 
and urinary or circulating dopamine was established . 
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I. INTRODUCTION 
Although much has been learned within the past several decades re-
garding the synthesis, distribution, physiological disposition and the 
role of the catecholamines in regards t o nerve physiology, little progress 
has been made in the possible role of these hormones in organic disease. 
Except in a few isolated cases such as pheochromocytoma, attempts at 
demonstrating a causal relationship to various organic disease states 
have resulted in failure. Because of the prominent pressor effects of 
the catecholamines on the cardiovascular system, there have been repeated 
attempts to show a relationship to hypertensive disease. Most of these 
studies have concerned themselves with the actions of norepinephrine and 
epinephrine and are inconclusive in their findings. For the most part, 
the catecholamine dopamine (3-hydroxytyramine) has been ignored even 
though it is known to possess rather powerful pressor effects. For this 
reason, DeFanti and DeFeo undertook a study of the possible role of this 
substance in the etiology of experimental renal hypertension in albino 
rats. Their findings showed an increased urinary excretion of dopamine 
which correlated with the severity of hypertension. 
The purpose of this problem was to extend their work in the hopes of 
further elucidating the possible role of dopamine in the etiology of renal 
hypertension. 
Early in the study it was discovered that Dowex 50W-X8 resin ex-
tracted a substance with native fluorescence from rat urine and that the 
blank utilized in the original study, that of Carlsson and Waldeck, 
quenched this native fluorescence. Therefore, a good portion of this 
study was directed towards the development of a reliable method for the 
6 
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assay of urinary dopamine. Also because of this finding, certain aspects 
of the ,original study had to be repeated. In addition to this, an attempt 
was made to demonstrate the presence of dopamine in the blood of hyper-
tensive rats and dogs, in the kidneys of hypertensive rats, and also to 
determine the extent of involvement of the kidney in the increased tissue 
levels of dopamine known to follow the intravenous infusion of dihydroxy-
phenylalanine (DOPA). 
/ 
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II. REVIEW OF LITERATURE 
Since the first successful production of sustained experimental 
hypertension by Goldblatt in 1934, numerous methods have been reported 
in the literature for the production of experimental hypertension. Most 
successful methods either directly or indirectly involve renal function; 
and as a consequence, etiological studies have centered their attention 
on the function of the kidneys and other systems known to exert an 
influence upon kidney function (i.e., the nervous and endocrine systems). 
DeFanti (1961) has extensively reviewed the literature in this area, 
and the interested reader is referred to his work for developments in 
the field prior to 1961. The present review will center its attention 
on more recent advances, making reference to the earlier works only where 
necessary to establish a background for the present discussion. 
There is by no means complete agreement on what initiates hyperten-
sion or maintains it. Most investigators, however, feel that renal 
hypertension is initially a consequence of one of the following: (1) the 
release of a substance from the kidney which in itself is not pressor, but 
which in turn causes the formation of an extra-renal pressor substance 
(i.e., the renin-hypertensin or angiotensin system), (2) retention of a 
pressor substance within the body due to impaired renal elimination or 
failure of the kidney to destroy pressor substances (i.e. renoprival hyper-
tension) or (3) the formation and secretion of an active pressor substance 
from within the ischemic renal tissue itself. There is evidence to 
support all of these theories, and yet the evidence cannot be considered 
conclusive for any. 
The renin-angiotensin theory probably receives the greatest support. 
Figure 1 depicts the proposed mechanism: 
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RENIN 
(An enzyme liberated from the 
juxtaglomerulus apparatus of 
the kidney during inadequate 
perfusion) 
+ 
l 
ANGIOTENSIN I 
9 
SUBSTRATE 
(A protein of hepatic origin 
contained in the Alpha-2-
globulin fraction of the 
plasma) 
(An inactive(?) dexapep~ide) 
+ 
ANGIOTENSIN II 
Converting enzyme (found in 
plasma (and certain tissues) 
(The active octapeptide responsible 
for elevation of blood pressure) 
, Angiotensinases (found in plasma, 
kidney and many tissues) 
Inactive degredation products 
Fig. l. Pathway for the formation and destruction of Angiotensin II. 
(Formulated after Skeggs et al., 1967) 
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According to this theory, when ever t he kidney is endangered by inade-
quate perfusion pressure, it releases the enzyme renin. It in turn causes 
the formation of angiotensin II, which eleva tes the blood pressure by a 
vaso-constrictive action on the blood vessels--thus restoring adequate 
perfusion pressure. 
Research in this area was stimulated by the findings of Laragh et al. 
(1960) and Biron et al. (1961), who demonstrated that angiotensin II 
stimulates the release of aldosterone from the adrenal cortex, thus 
directly implicating the adrenals in the renin-angiotensin theory of hyper-
tension. A tie-in with the adrenals had been suspected for some time 
since Goldblatt (1951) found that the adrenals were necessary for the 
development of hypertension following renal ischemia. Helmer et al~ (1951) 
presented evidence to suggest that the adrenal steroids are necessary for 
maintenance of renin substrate in the plasma. 
If hypertension is caused by this mechanism, one would expect to 
find not only elevated levels of angiotensin II but aldosterone as well. 
The evidence, however, is conflicting. Kahn et al. (1952) reported only 
slightly elevated angiotensin levels in benign essential hypertensive 
patients, but levels twenty times the norm in malignant hypertensive · 
patients. Skeggs et al. (1958) obtained similar results. On the other 
hand, Haynes et al. (1947) and Taquini et al. (1958) found no evidence of 
elevated angiotensin levels. More recent work is no less confusing. 
Genest et al. (1964) failed to demonstrate consistently elevated angio-
tensin levels in dogs with experimental malignant hypertension, while 
Scornik et al . (1961) failed to demonstrate abnormal levels in the human 
form of this disease. Mulrow et al. (1964) also failed to detect appreci-
able angiotensin II levels in renal hypertensive patients. However, 
Morris et al. (1964) consistently found angiotensin II to be elevated in 
renal hypertensive patients. It is quite possible that methodology has 
contributed to the confusion, 
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A similar situation exists for aldosterone. While Genest et al. 
(1958) found the mean urinary aldosterone level to be significantly 
elevated in a group of patients suffering from essential, renal, and 
malignant hypertension, 57% of the individual patients were within the 
normal range. Laragh (1960a; 1960b) found consistently elevated aldo-
sterone levels in malignant hypertension, but could find no abnormality 
in benign essential hypertension. In a subsequent study (Laragh et al., 
1966), the aldosterone level in uncomplicated essential hypertension was 
either normal or low. 
An interesting observation was made by Ames et al. (1965) when they 
discovered that prolonged infusions of angiotensin in human subjects, on 
a normal sodium diet, resulted in an increase in vascular sensitivity to 
angiotensin. Over the period of the infusion (up to 11 days), less and 
less angiotensin was required to maintain a consistent pressor response. 
In addition, the secretion of aldosterone was found to decrease to near 
normal levels as the dose of angiotensin was decreased. These findings 
were attributed to sodium retention and a resulting increase in vascular 
sensitivity since a group of subjects on a low-salt diet did not develop 
increased sensitivity . On the basis of these findings, Laragh (1967) has 
proposed a possible mechanism for the development of hypertension in which 
neither angiotensin or aldosterone levels remain permanently elevated. 
Supposedly, the process is initiated by a primary• renal disturbance, 
causing the formation of excessive angiotensin levels~which in turn 
increase the secretion of aldosterone from the adrenal cortex. Sodium 
12 
retention and hypertension develop and act in concert to suppress further 
formation of angiotensin. Eventually a point is reached where the angio-
tensin blood level drops below the concentration necessary to stimulate 
aldosterone production, and the levels of the steroid return to normal. 
However, the increased vascular sensitivity to angiotensin, as a result 
of elevated intravascular stores of sodium, maintains the hypertensive 
state despite the return of angiotensin levels to normal values. 
The above data indicate that renin, angiotensin, and aldosterone 
most likely play a role in certain phases or types of hypertensive disease. 
Yet there are discrepancies which have not been adequately explained: the 
rapid return of blood pressure to normal when the circulation to a clipped 
kidney is restored and the contralateral kidney removed, but in addition, 
the maintenance of hypertension when the clipped kidney is removed and 
the contralateral kidney left in place (Tobian et al., 1959). An investi-
gation into this phenomenon by Singer et al. (1963) found the secretion of 
aldosterone to be elevated in hypertensive rats in which one renal artery 
was clipped and the other kidney unaltered but not in rats with one renal 
artery clipped and the contralateral kidney removed. It is also difficult 
to understand the failure of severe salt restriction to lower blood pressure 
in renal hypertensive rats (Redleaf and Tobian, 1958) or the failure of 
diets low in salt content to lower blood pressure in more than two-thirds 
of all hypertensive patients (Corcoran, et al., 1951). 
Evidence in support of the renoprival theory of hypertension is 
limited. Grollman et al. (1949) were the first to demonstrate the develop-
ment of hypertension in animals following removal of both kidneys. 
Muirhead et al. (1956) suggested that normal kidneys secrete a substance 
with antihypertensive properties and that hypertension results when the 
I .J 
kidneys fail to secrete this substance. Later it was demonstrated that 
peritoneal implantation of renal medullary tissue prevents the development 
of renoprival hypertension (Muirhead et al., 1959), and in 1966 a lipid 
displaying antihypertensive properties was isolated from the medullary 
tissue (Muirhead et al., 1966). It was proposed that functional renal 
tissue is necessary for maintenance of the normotensive state. Mendlowitz 
et al. (1961) state that it is not as yet known if there is a human 
counterpart for this type of experimental hypertension • . 
The catecholamines, in pa:ticular, norepinephrine (NE) and epine-
phrine (E), have long been suspected of playing a role in the etiology of 
hypertension primarily because of their prominent actions on the cardio-
vascular system. However, as Pert (1966) points out, there is hardly any 
evidence of credit which implicates increased circulating catecholamines 
in ordinary cases of hypertension with the noteable exception of pheochromo-
cytoma. Therefore, if E or NE is to be implicated, some change must be 
demonstrated in either their synthesis, degradation, storage, release, or 
sensitivity of the vascular wall to locally released NE. 
The synthetic pathway for the formation of the catecholamines has now 
been well established with the isolation and characterization of tyrosine 
hydroxylase by Nagatsu et al. (1964). Although this enzyme was the first 
to be involved in the synthesis of the catecholamines, it was the last to 
be isolated and characterized. The major pathway for the synthesis of NE 
and E is shown in Figure 2. 
Tyrosine hydroxylase seems to be localized in subcellular particles 
which sediment at 15,000 to 20,000 x g (i.e., the mitochondrial fraction) . 
++ It Fequires a tetrahydropteridine cofactor, Fe and oxygen (Udenfriend, 
1966). L-Dopa decarboxylase (aromatic L-amino acid decarboxylase) activity 
'-. 
K~l+<"' 
/ EPININE ~ .,Qij:~~ .,-QH::"' 0 • "'-Q1:b. ... "~r!i:_. "~~H~ 
. H 5 H 2 H 3 ·· H 3 OH 
DOPA DOPAMINE NOREPINEPHRINE EPINEPHRINE NtiETHYL 
., ; INEPHRI NE 
r6 ,r i6 
~ t OH ~+"2 ~HH (Di" i }"J HOH =~H2 I> 
.. 
~-NH2 - -\ 
HO HO I> HO 
5 2 3 
TYROSINE TY RAM I NE OCTOPAMINE SYNEPHRINE 
Fig. 2. Main and alternate pathways in the formation of catecholamines: 1) tyrosine 
hydroxylase, 2)~ dopamine-13 -oxidase, 3) phenylethanolamine- N-methy l transferase, 
4) nonspecific N-methyl transferase in lung, 5) aromatic amino acid decarboxylase, 
6) catechol-forming enzyme (After Axelrod, 1966). 
...... 
+' 
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remains in the supernatant fraction foll owing high-speed centrifugation 
and is not, therefore, particle bound (Lovenberg et al.; 1962). This 
enzyme requires pyridoxal phosphate as a cofactor (Green, 1945). Dopamine-
~-oxidase activity has been linked to the chromaffin granules of the 
adrenal medulla (Levin et al., 1960; Oka et al., 1967) and the granulated 
vesicles of sympathetic nerve endings (Potter et al., 1963). It requires 
oxygen, ascorbic acid, and a dicarboxylic acid as cofactors (Levin et al., 
1960). Phenylethanolamine-N-methyl transferase is for the most part con-
fined to the adrenal medulla in mammals and is found in the supernatant 
of cell homogenates. It requires S-adenosylmethionine as a methyl donor 
(Axelrod, 1962a). Tyrosine is readily available in the circulation in 
levels of 10-15 mg/l (Spector et al., 1963). It is therefore presumed 
that tyrosine is taken up into sympathetic nerve endings and other sites 
.of catecholamine synthesis by an active transport system similar to that 
acting in the brain (Chrivos et al., 1960). Within the cell, tyrosine 
passes from the cytoplasm to the mitochondria where it is converted to 
3,4-dihydroxyphenylalan,ine (DOPA) which returns to the cytoplasm where it 
is decarboxylated to dopamine (DM). Finally, DM enters the granulated 
vesicles where it is converted to NE. In the adrenal medulla some of the 
formed NE passes back into the cytoplasm where it is converted to E. The 
Ethen re-enters the granulated vesicles for storage (Axelrod, 1966). 
The available evidence supports tyrosine as the immediate precursor 
from which the catecholamines are synthesized. In addition to being 
readily available in the circulation (hoc. sit), adequate levels are main-
tained even in starvation states (Melman et al., 1964), Other possible 
precursors such as DOPA or DM are not readily available in the circulation 
(Anton et al., 1964). 
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Factors controlling the rates of catecholamine synthesis are not yet 
fully understood. Udenfriend (1966) presents rather convincing evidence 
that tyrosine hydroxylase activity repres ents the rate-limiting step in 
NE synthesis: Of the three possible precursors (i.e. tyrosine, DOPA 
and DM), saturation could be achieved only with tyrosine. The Vmax for 
tyrosine hydroxylase is two or three orders of magnitude lower than the 
values for DOPA decarboxylase or dopamine-~-oxidase, its activity being 
expressed in millimicromoles of tyrosine oxidized per gram of tissue per 
hour compared with micromoles of DOPA or DM converted per gram of tissue 
per hour. Thus, tyrosine hydroxylase becomes limiting because the amount 
of enzyme is limiting. Studies with inhibitors add further support. 
« -Methyl-p-tyrosine, ~-methylphenylalanine, 3-iodotyrosine, 3-iodo-
«-methyltyrosine and Hassle 22/54, all inhibitors of tyrosine hydroxy-
lase, lower tissue levels of NE when administered to animals. However, 
disulfiram, which inhibits dopamine-~-oxidase, will also lower tissue 
levels (Musacchio et al., 1964). In contrast, benzyloxyamine and certain 
benzylhydrazine analogs, also inhibitors of dopamine-P..oxidase, will not 
lower NE levels appreciably in vivo (Nikodijevic et al., 1963). There is 
therefore a possibility that under certain circumstances dopamine-P-oxidase 
could be rate-limiting. DOPA decarboxylase cannot be considered rate-
limiting since it apparently cannot be inhibited sufficiently to interfere 
with catecholamine synthesis (Hess et al., 1961) . 
Factors other than enzyme activity could conceivably influence the 
rate of catecholamine biosynthesis. Availability of substrate, enzyme 
cofactors, and integrity of the cellular compartments may play a role. In 
regard to this latter point, i t has been shown that reserpine depresses 
NE synthesis in sympathetic nerves possibfY by causing damage to the 
granulated vesicles (Dahlstrom et al., 1965). The activity of the sympa-
thetic nervous system itself may play a role. NE synthesis from tyrosine 
is depressed in the denervated submaxillary gland (Musacchio and Weise, 
1965). However, available evidence, though sparse, suggests that sympa-
thetic tone is normal in hypertension (Pickering, 1936; Pert, 1966). 
Since an increase in synthesis of the catecholamines would necessarily 
be reflected by an increase in their degradation products, it is necessary 
to have an understanding of the basic mechanisms of catecholamine meta-
bolism. A great deal of advancement has been made in .this area within 
recent years. Basically two enzymes are involved in the metabolic 
degradation of the catecholamines: Monoamine oxidase (MAO) and catechol-
0-methyl transferase (COMT). 
MAO is widely distributed in the tissues, being localized in the 
mitochondria (Blaschko et al., 1957). Especially large quantities occur 
in sympathetic nerve endings (Snyder et al., 1965). It appears that its 
role in catecholamine metabolism is limited to disposing of excess stored 
material within the sympathetic nerve endings (Koplin, 1964). MAO has no 
apparent role in the physiological inactivation of NE or E since near 
total inhibition of the enzyme has no effect on the physiological responses 
to either injected or nerve-released catecholamines (Burn et al., 1954; 
Griesemer et al., 1953). On the contrary, MAO plays an important role in 
regulating the tissue levels of the catecholamines. Marked inhibition of 
MAO leads to a rise in the tissue levels of NE and other endogenous amines, 
especially serotonin, DM and tyramine which serve as better substrates for 
MAO than NE and E (Koplin, 1964; Shore et al., 1957). In a latter publi-
catton, Shore (1966) points out the importance of MAO in regulating the up-
take and storage of biogenic monoamines in sympathetic innervated tissues. 
' J 
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Catechol-0-methyl transferase (COMT) is found in almost all tissues 
and is highly concentrated in the liver and kidneys (Axelrod and Tomchick, 
1958). COMT activity remains in the cytoplasm following high speed centri-
fugation and its function is considered to be extra-neuronal since tissue 
levels of NE are unaffected by the activity of the enzyme (Crout et al., 
1961). Axelrod (1966) presents extensive evidence to support the view 
that COMT acts primarily upon circulating amines and amines released from 
sympathetic nerve endings. In addition, he presents additional evidence 
to implicate the enzyme, phenylethanolamine N-methyl transferase (PEMT) 
in the metabolism of NE. The major, and some minor, pathways for the 
catabolism of NE and E are shown in Figure 3. 
The three major excretory products of NE and E are 3-methoxy-4-
hydroxymandelic acid (vanilylmandelic acid; VMA), normetanephrine (NMN) 
and metanephrine (MN) (Armstrong et al., 1957; Axelrod and Tomchick, 1958). 
'!be major portion of VMA in the urine probably represents NE produced and 
deaminated within the nerve ending before it has a chance to produce a 
physiological effect (Kopin, 1964). Therefore, NMN for the most part 
represents NE which has been physiologically discharged from the sympa-
thetic nerves. 
There have bee~ surprisingly few well-controlled studies regarding E 
and NE levels in ordinary cases of hypertension. Euler et al. (1954) 
found some evidence of increased excretion of free and conjugated NE in a 
limited number of hypertensive patients. Romano et al. (1966) reported 
urinary VMA levels to be approximately twice as high in hypertensive sub-
jects as compared to control values. Stott and Robinson (1967) found NMN 
excretion higher in hypertensives. However, the majority of investigators 
have failed to find any cons i s tent elevation in tissue or urinary levels 
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of E, NE or their metabolites in hypertensive disease(Brunjes, 1964; 
Gitlow et al., 1963; Gitlow et al., 1962; Petrasek et al., 1966; Sjoerdsma, 
1961; Raab, 1961; Wegmann et al., 1962). 
It is quite possible tha NE could oarticipate in the hypertensive 
process at the local tissue level without giving rise to increased plasma 
levels or excretion rates, lf both the release and re-uptake of NE f rom 
its storage sites were increased, then increased sympathetic activity 
would be possible without any outward signs of NE involvement. Studies 
into the possibility of an increased local turnover have been rather 
limited. Gitlow et al. (1964), using tritiated NE, found a trend for 
decreased metabolic clearance in advanced hypertensive patients. Mend-
lowi tz et al. (1959) proposed a hypothetical deficiency of COMT in the 
vascular wall. However, Sjoerdsma et al. (1961) could show no deficiency 
of COMT or MAO activity in hypertension. Reciently DeChamplain et al. 
(1967) demonstrated decreased accumulation of tritiated NE in certain 
tissues of DOCA (desoxycorticosterone acetate) hypertensive rats. A 
highly significant inverse relationship was shown between blood pressure 
and both endogenous and labeled NE levels in the heart. They also demon-
strated an increase in NE metabolites in the hypertensive animals. A 
defect in amine storage was offered as a possible explanation. 
It is also possible for NE to participate in the hypertensive process 
at normal tissue levels if the vascular wall becomes over-responsive', 
There are a growing number of reports which suggest such a possibility 
(Raab, 1961; Doyle and Fraser, 1961; McCubbin and Page, 1963; Baum and 
Shropshire, 1967). Pert (1966) sheds doubt on the theory of increased 
vascular sensitivity and advocates caution in the interpretation of experi-
mental results. Additional studies are necessary in this area before the 
importance of these findings can be established. 
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Recent evidence suggests that angiotensin is a highly potent releaser 
of adrenal catecholamines (Feldberg and Lewis, 1964; Ibid. 1965). The 
implications are that the catecholamines may be involved in the renin-
angiotensin theory of hypertension. Other investigators, however, have 
not been able to confirm these findings. Vincent et al. (1965) could 
show no effect of angiotensin administration on VMA excretion in labile 
hypertensive subjects, and Healy (1967) also could not show any effect 
on ei the.r VMA or urinay catecholamine excretion rates. 
One would have to conclude tha~ no convincing evidence currently 
exists to directly implicate NE or E in the hypertensive process, but 
one would equally have to conclude that there is no convincing evidence 
which would completely exonerate them. 
The immediate precursor to NE, dopamine (DM), has received very 
little attention as a possible participant in the hypertensive process. 
And yet, DM possesses.all the attributes of a vasoactive substance. It 
is pressor in the cat 0Roltz et al., 1963), predominantly so in the dog 
(Goldberg and Sjoerdsma, 1959; Maxwell et al., 1960; Holmes and Fowler, 
1962; McDonald and Goldberg , 1963), in man (Horwitz et al., 1962; Allwood 
and Ginsburg, 1964), and in the rat (Holtz et al., 1942). Most of these 
investigators attributed the pressor response to an increase in cardiac 
output since peripheral resistance was found to either decrease or remain 
relatively unaffected. Small doses of DM, its administration following 
drugs which block the alpha receptors, and usual doses in the rabbit or 
guinea pig result in a depressor response which is unaffected by prior 
administration of beta adrenergic blockers (McDonald and Goldberg, 1963; 
Vanov, 1963; Holtz et al., 1963; and Eble, 1964). These findings would 
suggest that the presser effect of DM is at least partially due to action 
21 
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on the alpha receptors while the depressor response results from an 
action other than stimulation of beta receptors. Prior administration 
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of reserpine does not affect the response to DM but completely prevents 
the usual pressor response to tyramine, a potent releaser of NE (McNay 
and Goldberg, 1966). In addition, Stone et .al. (1963) showed that DM 
does not deplete tissue catecholamines. These findings, coupled with 
those of Horwitz et al. (1960) who showed that MAO inhibition greatly 
augmented the pressor response of DM but had little effect on the pressor 
response to NE, would suggest that DM itself is pressor and does not act 
by releasing NE or by enzymatic conversion to another catecholamine. 
Horwitz et al . (1962) have estimated the pressor potency of DM to be 
1/25 t.o 1/ 50 that of NE in man. 
Dopamine is widely distributed in the tissues. Schumann (1959) 
reported DM to comprise 2% of the total catecholamines in the adrenal 
medulla, 50% in sympathetic nerves and ganglia, 90% in the liver, 98% in 
the lungs and 30 to 50% of the total catecholamines in the spleen, pan-
creas parotid gland, and brain. Euler and Lishajko (1957) reported 
similar findings for lung and spleen. Other investigators have not been 
able to confirm the presence of large quantities of DM in mammalian 
tissues. Wegmann (1963) could detect the presence of DM only in the 
spleen and kidney of the dog. Anton and Sayre (1964) generally found DM 
tissue levels to be low, except in the brain for which their values were 
in general agreement with those of Carlsson (1959). These same authors 
were unable to detect the presence of either DM or DOPA in the plasma of 
humans, dogs, or rabbits, 
As the immediate precursor to NE, DM is taken up from the ~ytoplasm 
of sympathetic nerves by granulated vesicles in the nerve endings 
;~ , 
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(Kirshner, 1962; Musacchio et al., 1964) and oxidized to NE (Levin et al., 
1960; Potter and Axelrod, 1963). Recently an enzyme has been found in 
rabbit lung which will N-methylate DM to form epinine (Axelrod, 1962b). 
Dopamine-beta-oxidase will hydroxylate epinine to E (Bridgers and Kauf-
man, 1962), thus establishing ·a minor pathway for the synthesis of E. The 
major metabolic pathway for the degredation of DM leads to the formation 
of homovanillic acid (HVA) Hornykiewicz, 1966). There is evidence, at 
least in the brain, that DM is first attacked by MAO leading to the forma-
tion of 3,4-dihydroxyphenylacetic acid which is subsequently 0-methylated 
by COMT to produce HVA (Anden et al., 1963; Carlsson and Hillarp, 1962). 
Carlsson and Waldeck (1964) have reported the normal occurrence of small 
amounts of 3-methoxytyramine in the brain and a considerable increase 
following administration of MAO inhibitors. This would indicate that 
small amounts of DM may be 0-methylated prior to oxidative deamination. 
It seems logical that MAO should be the first enzyme involved in the 
catabolism of DM in light of what is known about the tissue distribution · 
of DM and MAO. Both the enzyme and its substrate are concentrated within 
sympathetic nerve endings (hoc.sit.), and there is no good evidence to 
suggest that dopamine is normally released as a consequence of nerve 
stimulation. The major pathways for the synthesis and catabolism of DM 
are presented in Figure 4. 
Dopamine and its metabolites are known to increase in the urine in 
neuroblastoma (Kaser, 1966), melanoma (Duchon and Gregora, 1962), familial 
dysautonomia (Smith et al., 1963) and malignant pheochromocytoma (Robinson 
et al., 1964); but the possible role of DM and its. metabolites in hyper-
tension have been given only passing interest. Bischoff and Torres (1962) 
report the urinary excretion of DM to be within the normal range in a 
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very limited number of hypertensive patients, and Petrasek et al. (1966) 
reported HVA excretion to be normal in a larger number of patients. The 
only study dealing directly with the possible role of DM in hypertension 
appears to be that of DeFanti and DeFeo (1963). These investigators 
found the urinary excretion of DM elevated in renal hypertensive rats 
and found a positive correlation between the blood pressure in these 
animals and the logarithm DM concentration. 
The findings of DeFanti and DeFeo (1963), the established pressor 
activity of DM in man and animal, and the lack of controlled studies into 
the possible involvement of DM in renal hypertension suggest the need for 
further studies in this area. 
/ 
III. INVESTIGATION 
A. OBJECTIVES 
The objectives of this i nvestig ~ion a re as follows: 
1. To develop a reliable method for the assay of dopamine in 
rat urine. 
2. To detennine if t h ,n , urinary excretion 
of dopamine in rats and dogs rendered hypertensive by r ena l fs chemia. 
3. To detennine if the arterial blood pressure is sig .1 i ficantly 
dependent upon the increase in dopamine production. 
4. To detennine the role of the kidney in the elevation of tissue 
dopamine levels which follow the administration of dihydroxyphenylalanine. 
B. MATERIALS AND METHODS 
l. Production of Experimental Hypertension 
Male albino rats of the Sprague Dawley strain weighing 90 to 100 g 
were used for this investigation. Experimental renal hypertension was 
111 I 11 ' •I" 
induced by a two-stage operation under ether anesthesia according to the 
method of Goldblatt et al. (1934) as modified by Dury (1938). The first 
consisted of removal of the right kidney through a dorsal incision; and 
the second, compression of the left renal artery. A period of two weeks 
separated the two operations to allow uime for the animals to recover and 
to carry out the procedures listed below. Compression of the left renal 
artery was carried out in the following manner: The artery was located 
through a ventral midline incision in the lower abdomen and carefully 
separated from the renal vein and surrounding connective tissue. A wire 
stylus obtained from either a 19-, 20- or 21-gauge needle was laid alongside 
the artery, the choice of size being based upon an attempt to produce a 
_26 
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reduction in renal blood f ~ow of at least 50%. A silk ligature was then 
double-knotted around both the artery and stylus, temporarily cutting off 
renal blood flow. The stylus was then carefully removed, leaving the 
ligature in place. The muscle layer was sutured and the skin incision 
closed with wound clamps. The rats were divided into three groups of 16 
each and housed 8 to a cage. 
A group of sham-operated rats served as controls and was run con-
currently with the experimental groups. These animals were also subjected 
to two operations: the first, removal of the right kidney; the second, 
manipulation of the left renal artery. The indirect systolic blood 
pressure of each animal was obtained initially at weekly intervals and 
then at two-week intervals. An Infraton1 unit connected to a sensitive 
oscilloscope (1 mV/cm deflection) was used to obtain a pulse wave from 
the tail. A special plexiglass holder was devised for the pressure-sensitive 
microphone which, with a screw, permitted adjustment of the pressure 
applied to the microphone in order to obtain the maximum pulse wave. A 
rat tail cuff attached to an aneroid manometer was placed proximal to the 
I 
microphone on the rat s tail. The cuff was inflated to a pressure well 
above the anticipated systolic pressure. Systolic blood pressure was 
recorded as that point, to the nearest 5 mm Hg, where the pulse wave returned 
as the pressure was slowly released from the cuff. As temperature variation 
was found to create difficulties in obtaining an adequate pulse wave, all 
determinations were carried out in a constant temperature room at 25° C. 
2. Collection of Urine 
Following the blood pressure determinations, rats within the same 
1. Beckman Instruments Inc., Spinco Division, Palo Alto, California. 
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group having the same or nearly the same blood pressures were paired and 
placed in stainless steel metabolism cages to collect 24-hour urine 
samples. A sufficient quantity (4-5 drops) of concentrated sulfuric acid 
was added to the collection vessel to insure an acid milieu in order to 
prevent breakdown of urinary catecholamines. The total urinary output 
for 24 hours was recorded in ml and the samples frozen at -4o0 c for sub-
sequent determination of dopamine content. 
3. Collection of Blood Samples 
At the end of the experiment each of the surviving rats was 
sacrificed by decapitation and the blood collected. A small amount of 
heparin was added to each tube to prevent coagulation. The samples were 
then centrifuged to separate the plasma, which was removed and frozen for 
subsequent dopamine assay. 
4. Comparison of Kidney Dopamine Content 
An additional group of hypertensive rats was prepared for the 
purpose of determining any changes in the renal tissue content of dopamine 
which might be associated with the hypertensive state. Under ether anes -
thesia the right kidneys were removed, blotted to remove excess blood, 
weighed, and then frozen in liquid nitrogen and stored at -4o0 c to await 
assay for dopamine content. Eight weeks following the second operation, 
the surviving rats were sacrificed by decapitation, and the left kidneys 
removed and treated as above. The blood from these animals was pooled to 
form one large sample which was subsequently assayed for dopamine content. 
The blood pressure of these animals was recorded only twice: just prior to 
the initial operation while under ether anesthesia and just prior to sacri-
fice, again under ether anesthesia. 
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5. Hypertensive Dogs 
One female mongrel dog and one male mongrel dog were also rendered 
hypertensive by a two-stage operation. In the first procedure the right 
kidney was removed under pentobarbital anesthesia, 30 mg/kg, through an 
incision made in the dorsal surface just below the rib cage. A double 
silk ligature was tied around the renal artery, vein and ureter near the 
renal pelvis. A cut was made proximal to these ties, and the kidney was 
then removed. Care was exercised to prevent damage to the adrenal gland. 
The muscle incision was closed with chromic gut and the skin with dermal 
silk. After a two-week recovery period, the second stage of the operation 
was carried out, again under pentobarbital anesthesia. An incision was 
made in the linea alba from the xyphoid process to include the umbilical 
scar. The left renal artery was freed from the renal vein and stripped 
clean of fascia. A silk ligature was placed underneath the artery; and a 
metal stylus, prepared from a series of common finishing nails, was 
selected with the intent of reducing the lumen of the artery approximately 
50% and was laid alongside the artery. A double-knotted tie was then 
completed around both the artery and the stylus, momentarily cutting off 
renal blood flow. The stylus was then removed, restoring renal blood flow 
but leaving a constriction in the artery. The loose end of the ligature 
was anchored to the dorsal muscle surface to prevent slippage. The incision 
was then closed in the usual manner. Two dogs were utilized as controls. 
One male underwent surgical removal of the right kidney and simultaneous 
manipulation of the left renal artery to serve as a sham-operated control; 
the other, a male, served as an unoperative control. All surgery was 
carried out under aseptic technique, and post-operative antibiotics were 
utilized to minimize the chances of infection. 
Weekly blood pressure recordings were obtained from the tail of the 
dogs using the Infraton unit and finger-occluding cuff attached to an 
aneroid ~anometer. Twenty ml blood samples were collected at weekly 
intervals using EDTA-charged Evacuettes2 • The dogs were also placed in 
metabolism cages each week for collection of 24-hour urine samples. Some 
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difficulty was encountered in getting the dogs to void while within the 
confines of the metabolism cage, and 5 mg of Urecholine c13 subcutaneously 
was occasionally employed to force emptying the bladder. Sulfuric acid 
was again utilized to provide an acid environment during the collection 
period. The total urinary output for 24 hours was recorded and an aliquot 
taken and frozen along with the blood samples at -4o0 c for subsequent 
dopamine assay. 
6. Cat Infusion Studies 
A separate experiment was undertaken in cats to determine the role 
of the kidney in the elevation of tissue dopamine levels known to occur 
following infusion of d,1-dihydroxyphenylalanine (Wegmann, 1963). Two 
female cats and two male cats were sacrificed as controls to determine 
endogenous levels of dopamine . They were first anesthetized with sodium 
pentobarbital 35 mg/kg intraperitoneally, then cardiac standstill was produced 
by the intravenous administration of potassium chloride. The heart, left 
kidney, spleen and one lobe of the liver were removed, blotted dry and 
their weights recorded. The organs were immediately placed in 10% trichloro-
acetic acid and homogenized in a Virtis 1145 114 homogenizer. The mixture was 
2. A product of Becton, Dickinson & Co., Rutherford, New Jersey 
I 3. •Merck, Sharpe & Dahme s Trade Name for Bethanechol Cl. 
4. The Virtis Co. Inc., Division of Cenco Instruments, Gardiner, New York 
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transferred to centrifuge tubes and centrifuged at 12,000 RPM for 20 
minutes in a Lourdes Model AB centrifuge to separate the clear superna-
tant. The volume of the supernatant was adjusted to 50 ml with lOi. 
trichloroacetic acid and a 25 ml aliquot utilized for the detennination 
of DOPA and dopamine. 
In four other cats, d,l-DOPA5 50 mg/kg was infused into the femoral 
vein over a 20-minute period. Sodium pentobarbital 35 mg/kg was used as 
the anesthetic. An arterial catheter was inserted into the abdominal 
artery via the femoral artery t o a point just below the origin of the 
left renal artery for the purpose of obtaining 5 ml blood samples midway 
through the infusion period and one hour after initiation of the infusion. 
A catheter was likewise inserted through the left ovarian vein or the left 
spennatic vein into the left renal vein to obtain corresponding venous 
blood samples. The right renal artery and vein were completely ligated 
in these experiments. One hour after starting the infusion, the cats 
were sacrificed by an iv injection of potassium chloride and the heart, 
left kidney, spleen and a lobe of the liver removed and treated as described 
above. The blood samples were immediately treated by the addition of 10 ml 
of lOi. trichloroacetic acid. 
In four additional cats 50 mg/kg of d,1-DOPA was infused as above 
except that both renal arteries and veins were tightly ligated to remove 
the kidneys from the general circulation. Blood samples were not taken in 
these animals since they would not be representative of a renal A-V 
difference. The heart, spleen and a lobe of the liver were removed as 
previously described and .assayed for their dopamine and DOPA content. 
5. d, 1-dihydroxyphenylalanine was obtained from Nutritional Biochemicals 
Corp., Cleveland 28, Ohio. 
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By a comparison of the results from these studies, it was hoped that 
the contribution of the kidney to tissue levels of dopamine in the heart, 
liver and spleen could be determined. 
7. Determination of Dopamine and DOPA 
With certain modifications, the trihydroxyindole method of Carlsson 
and Waldeck (1958) was used for the fluorimetric estimation of dopamine 
and DOPA. The blank as employed by these investigators left out sodium 
sulfite, which is included as an ingredient in one of the reagents used 
to develop the fluorophore of.dopamine and DOPA. The omission of this 
substance allows a faint iodine color to remain in the blank which acts 
as a quenching agent resulting in erroneously low blank values. In the 
present procedure sodium sulfite was added out of the normal sequence, 
following the addition of all other reagents. Thus, the blank utilized 
in the present procedure contains all of the chemicals found in a standard 
assay solution. Additional modifications of the original method included: 
adjustment of the strength of certain of the reagents, alterations of 
reaction times and heating the solution prior to UV irradiation. The 
necessary reagents and a description of the development procedure which 
was used, are as follows: 
0.1 M Phosphate buffer pH6.5 Dissolve 5.34 g Na2HP04, 2 H20 
in 500 ml of water. Dissolve 9.52 g KH2P04 (Sorensen) in 
500 ml water. Add the former solution to the latter, utilizing 
a pH meter to adjust the pH to 6.5. 
Iodine Solution Dissolve 0.252 g iodine and 5.0 g potassium 
iodide in 100 ml water. 
4.5 N Sodium Hydroxide Solution 
Alkaline Sulfite Solution Dissolve 5.04 g Na2S03, 7 H20 in 
10 ml water and dilute with 5 N sodium hydroxide to 100 ml . 
6 N Acetic Acid Solution Dilute 34.2 ml glacial acetic acid 
with water to 100 ml. 
·-. 
Sodium_Sul f ite Solution 
ml water. 
Glass distilled water was used throughout. 
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A three ml aliquot of a column eluate (see sections 8, 9, 10, 11) was 
transferred to a 15 ml volumetric centrifuge tube and the pH adjusted to 
6.5 by the addition of one ml of 0.3 M potassium carbonate in the case of 
a 0.2 N acetic acid eluate or by the dropwise addition of 5.0 M potassium 
carbonate to a 2.0 N hydrochloric acid eluate followed in either case by 
. the addition of one ml phosphate buffer pH 6.5. One-tenth of a ml of 
iodine solution was added to the tube, the contents mixed and allowed to 
react for three minutes. Then one ml of alkaline sulfite reagent was 
added, the contents mixed and this reaction allowed to proceed for four 
minutes. Finally, the pH of the solution was adjusted to approximately 
5.4 by the addition of one ml of 6 N acetic acid and the final volume 
adjusted to 10 ml by the addition of distilled water. The tube was then 
transferred to a boiling water bath for five minutes, cooled and centri-
fuged. Two to 3 ml of the resultant solution was transferred to a fused 
quartz cell and irradiated under a short wave (254.,..,...., mercury lamp for 
10 minutes. 6 The fluorescence of the solution was read in an Aminco- . 
Bowman Spectrophotofluorometer7 at an activating wavelength of 325-m)'V 
and a fluorescent wavelength of 380TnfV(1uncorrected instrument values). 
' A blank was determined for the assay by utilizing an additional 3 ml 
column aliquot and treating it as outlined above except that 4.5 N NaOH 
was substituted for the alkaline sulfite reagent and O.l ml of sodium 
6. Chromato-Vue, Black Light Eastern Corp., New York, New York. 
7. Aminco-Bowman Spectrophotofluorometer, American Instrument Co., Inc., 
Silver Springs, Maryland. Specifications for the test: Xenon Lamp, 
Slit Arrangement Number 5, Photomultiplier Tube iP28. 
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sulfite solution was added to 9.9 ml of the resultant solution just prior 
to centrifugation. The procedure allowed the handling of up to 18 samples 
at one time. 
Estimation of dopamine or DOPA content in the developed solutions 
was made by dividing the corrected fluorescent intensities of the unknowns 
by a value calculated to represent the fluorescent intensity of a solution 
of dopamine or DOPA containing 0.1 pg/ml. This standard value was deter-
mined each time a series of unknowns was assayed to guard against deter-
ioration of the reagents and day-to-day variation in fluorescent intensity 
and was obtained in the following manner: Acidic solutions of dopamine 
or DOPA to give final concentrations of 0.05, 0.1, 0.2 and 0.3 pg/ml and 
a blank were subjected to the procedures outlined above. These concentra-
tions were all within the range of linearity reported by Carlsson and 
Waldeck (1958), confirmed by DeFanti (1961) and supported by the present 
work. Correction for fluorescence contributed by the reagents was made 
by subtracting the fluorescent intensity of the blank from the fluorescent 
intensities of the standard solutions. These corrected values were then 
adjusted and averaged to obtain a single ~alue representing the fluorescent 
intensity of a 0.1 pg/ml solution of dopamine or DOPA. The following 
formulas sununarize the mechanics: 
Is = [ (Fs - R.B.x 0. 1 c ) /n 
where ls= fluorescent intensity of a 0.1 pg/ml solution of dopamine or 
DOPA 
F = uncorrected fluorescent intensity of the developed solutions 
s 
at concentration C 
R.B. = fluorescent intensity of the reagent blank 
C = final concentrations of dopamine or DOPA in pg/ml 
n = the number of determinations 
-. 
and finally: 
where = 
Fu = 
Bu = 
Is = 
the concentration of dopamine or DOPA Cpg/ml) in the 
developed solution of the unknown 
the uncorrected fluorescence intensity of the developed 
solution of the unknown 
the fluorescent intensity of corresponding blank of the 
unknown 
the fluorescent intensity of the standard as determined 
above 
Since the final volume of the developed solutions was 10 ml, the 
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total dopamine or DOPA content of a 3 ml column aliquot was equivalent to 
10 times the concentration in pg/ml (10 Cu) and the total in a 10 ml eluate 
to 100 Cu/3. The total amount of dopamine or DOPA in a sample was then 
calculated by the use of the following formula: 
3 
where Dt = the total quantity (pg) of dopamine or DOPA in a sample 
= 
= 
= 
the volume (ml) of the sample extracted for dopamine or 
DOPA content 
the total volume (ml) of the sample 
the concentration of dopamine or DOPA (pg/ml) in the 
developed solution of the unknown 
8. Extraction of Catecholamines from Urine 
Following modificat i on of the blank as outlined above, it was 
discovered that the sodium form of Dowex 50W-X8 was extracting a substance 
from rat urine which displayed native f luorescence interfering with the 
estimation of dopamine. It was theref ore necessary to develop a different 
method for the extraction of catecholamines f r om urine other than that 
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employed in the original study (DeFanti, 1961; Crawf ord and Law, 1958 ; 
Bertler et al., 1958). Various methods of absorption on alumina at pH 8 .4 
were tried (Weil-Malherbe and Bone, 1952; v. Euler and Lishajko, 1953; Weil-
Malherbe, 1961; Weil-Malherbe, 1964; Small, 1963) and found to avoid the 
problems encountered with Dowex. The final extraction method as outlined 
below is an adaptation of these various methods incorporating what was 
found by trial and error to give the best urinary recoveries of dopamine. 
Alumina for chromatographic analysis supplied by British Drug Houses, 
LTD8 was found to possess the most desirable characteristics and was used 
in this investigation. Prior to use, the alumina was suspended in 500 ml 
of 2 N hydrochloric acid and heated to 80°C for 20 minytes with constant 
stirring, filtered onto a glass-sintered filter and washed with an addi-
tional 500 ml of 2 N hydrochloric acid. The alumina was then resuspended 
in 500 ml of glass-distilled water , stirred, allowed to settle for approxi-
mately 15 seconds and the water decanted to remove the alumina fines. 
This was repeated a total of 10 times, and then the alumina was dried at 
1050C overnight. Alumina columns were prepared by suspending 0.7 g of 
the acid-washed alumina in 10 ml of 0.1 M ammonium acetate buffer pH 8.0 
and adjusting the pH to 8.4 by the addition of l N sodium hydroxide (the 
quantity of l N sodium hydroxide required was determined for each lot of 
alumina and was usually about 0.3 ml), The suspension was agitated f or 
one minute and then poured into a column previously filled with glass-
distilled water and plugged with a small pledget of cotton. The columns 
were constructed of 7 mm I.D. pyrex glass tubing drawn to a 4 mm O.D. tin 
8.·Exclusive United States Distributors: Gallard-Schlesinger Manufacturing 
Corp., 580 Mineola Avenue, Carle Place, Long Island, New York 11514 
' J 
to which polyethylene tubing was attached. The flow rate through the 
columns was regulated to 2 to 3 ml per minute, when necessary, by adjust-
able clamps on the tubing. NalgeneR funnels served as the reservoirs. 
The formed columns were washed with 5 ml of glass-distilled water and 
clamped until addition of the urine samples. Dog or rat urine aliquots 
were first centrifuged for 20 minutes in a clinical centrifuge and then 
10 ml (minimum 5 ml) transferred to large pyrex test tubes. Two drops 
of concentrated hydrochloric acid and 2.0 ml of 0.2 M ethylenediamine 
tetraaretic acid (disodium salt) were added to each tube. The tubes were 
stoppered with corks equipped with 21 g needles as relief valves and 
heated in a boiling water bath for 20 minutes to hydrolyze any dopamine 
present in conjugated form. The tubes were cooled and their contents 
transferred to plastic beakers using three 5 ml rinses of distilled 
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water. The pH of each was then adjusted to 8.4 with l N sodium hydroxide 
using a model 28 Radiometer automatic titrator9 and immediately added to 
an alumina column. One ml of 11. sodium metabisulfite was added to each 
sample during the pH adjustment to guard against oxidation of the cate-
cholamines before absorption onto the alumina. After passage of the urine 
samples, the columns were washed with 5 ml of l M sodium acetate followed 
by 5 ml of distilled water. Elution was performed by the addition of two 
separate 5 ml portions of 0.2 N acetic acid. All additions were made 
just as the meniscus of the previous solution entered the alumina bed. 
Three ml aliquots of the combined 10 ml eluates from the columns were then 
assayed for dopamine content as previously described. If this was not 
carried out within one-half hour, the eluates had to be frozen to prevent 
breakdown of their catecholamine content. 
9. Radiometer Copenhagen, 811 Sharon Drive, Westlake, Ohio. 
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Internal standards were run at various intervals throughout the 
experimental period by the addition of known amounts of dopamine to the 
urine prior to processing. The recovery values for these standards are 
recorded in Table 2, the average recovery being 82.43 ! 11.73 7. which is 
somewhat lower than the average recovery of 88.74 ! 5.93 % obtained for 
known concentrations of dopamine in 0.2 N acetic acid (see Table l). 
9. Extraction of Catecholamines from Rat Plasma 
Three methods were used to prepare the blood p.lasmas of the rats 
sacrificed at the termination of the experimental period for extraction 
of their catecholamine content. In one-third of the samples, the plasma 
proteins were precipitated with perchloric acid and centrifuged; in 
another third, the samples were hydrolyzed in 1.0 N perchloric acid at 
100° C for 10 minutes and centrifuged (Haggendal, 1963); the remaining 
10 
samples were passed through a column of Sephadex G-25 which separated 
the plasma into catecholamine and protein containing portions (Marshall, 
1963). The catecholamines were then extracted from the samples for 
fluorimetric assay using columns of the sodium form of Dowex 50W-X8 as 
subsequently described in section 11. 
10. Extraction of Catecholamines from Whole Blood and Tissues 
The tissues and whole blood samples from the other portions of 
this study were all extracted by homogenization in 10% trichloroacetic 
acid. These include the rat kidneys and pooled blood sample from section 
4, the blood samples obtained from the dog experiments (section 5) and 
the tissues and blood samples obtained from the cat infusion studies 
(section 6). Where only the dopamine content was under investigation, 
10. A product of Pharmacia Fine Chemicals, Inc., 800 Centennial Ave., 
Piscataway, New Market, New Jersey 08854 
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TABLE l 
Percent recovery of dopamine from 0.2 N acetic acid 
Dopamine Added <rg) Dopamine Found (~g) Percent Recovery 
2.00 l.80 90.00 
2.00 l. 93 96.50 
2.00 2.13 106.50 
2.00 l. 67 83.50 
2.00 l. 77 88.50 
2.00 l. 77 88.50 
4.00 3.57 89.25 
4.00 3.57 89.25 
4.00 3.57 89.25 
4.00 3.67 91. 75 
4.00 3.43 85.75 
4.00 3.43 85.75 
4.00 3.57 89.25 
6.00 4.90 81.67 
6.00 4.9,0 81.67 
6.00 5.47 91.17 
6.00 4. 77 79.50 
6.00 5.47 91. l 7 
6.00 5.23 87.17 
Mean recovery! standard deviation= 88.74 ! 5.93 7. 
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TABLE 2 
Percent recovery of dopamine added to urine samples 
Endogenous Dopamine Total Dopamine Percent 
Dopa.mine ()A- g) Added ( jJ- g) Calculated<r g) Found ()A- g) Recovery 
l.50 2.00 3.50 4.00 114. 28 
,,,. ' l.00 2.00 3.00 2.1 70.00 ; 
1.60 2.00 3.60 2.93 81.39 
l. 30 2.00 3.30 2.33 70.61 
2.73 2.00 4.73 4.03 85.20 
l. 27 2.00 3.27 3.07 93.88 
l. 70 2.00 3.70 2. 77 74.86 
2.07 2.00 4.07 3.33 81.82 
0.73 2.00 2.73 2.53 92.67 
1.10 2.00 3.10 2.10 67.74 
0.73 2.00 2.73 2.50 91.57 
0.83 3.00 3.83 3.57 93.21 
l.03 3.00 4.03 3.73 92.55 
0.87 3.00 3.87 2.73 70.54 
l.27 3.00 4.127 3.50 81.97 
l.57 3.00 4.57 3.67 80.31 
l.07 4.00 5.07 3.90 76.92 
l. 23 4.00 5.23 3.93 75.14 
0.93 4.00 4.93 3.53 71.60 
...... 
Mean recovery ! standard deviation = 82.43 ! 11. 73 '7. 
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the trichloroacetic acid extracts were passed through columns of alumina 
as described for urine. The samples from the cat infusion studies, how-
ever, were passed through a two-column procedure as described in the 
following section. 
11. Separation of Dopamine and DOPA 
A two-column procedure was used to separate dopamine from DOPA 
in the samples obtained following the infusion of d,1-DOPA in cats. The 
first column was prepared using the sodium form of Dowex 50W-X8 which 
has been shown by Bertler et al. (1958) to selectively bind dopamine 
while allowing DOPA to pass on through the column. The sodium form of 
the resin was prepared by cycling the resin first through 2 N hydrochloric 
acid followed by several washes with glass-distilled water, then through 
several changes of 5 N sodium hydroxide and finally washed with glass-
distilled water until the supernatant was neutral. The resin was then 
filtered by suction onto a glass-sintered filter and stored in moist 
form in a tightly stoppered bottle. The columns were prepared by sus-
pending 500 mg of the prepared resin in distilled water and pouring the 
mixture into columns constructed from the discarded barrels of 1 ml tuber-
culin syringes which had been previously filled with distilled water and 
plugged with small pledgets of cotton. After the columns had formed, 
10 ml of 1.0 N sodium acetate-acetic acid buffer pH 6.0 was passed 
through each column followed by 5 ml of distilled water. The columns were 
then ready for use. The samples were prepared for addition to the 
columns by selecting suitable aliquots of the trichloroacetic acid 
extracts, adjusting the pH to 6.5 with 5 M potassium carbonate, adding 
2 ml of 0.2 M ethylenediamine tetraacetic acid (disodium salt) and l ml 
of 17. sodium metabisulfite to each sample. As a sample passed through a 
,_, ( 
,. 
column (flow rate= 0.25 ml/minute), the effluent (E-1) was collected in 
a small plastic beaker resting on a magnetic stirrer which contained l 
ml of 2 N hydrochloric acid and a bar to permit continual agitation of 
the effluent. This was found necessary to prevent destruction of DOPA 
in the effluent. The column was then washed with two 10-ml portions of 
distilled water which was combined with the effluent (E-1). The dopamine 
was then eluted from the column using two separate 5 ml portions of 2 N 
hydrochloric acid. A 3 ml aliquot of this was assayed for dopamine 
content as previously described. The volume of the combined effluent 
and washings (E-1) was adjusted to 50 ml with distilled water, and a 5 ml 
aliquot taken for extraction and assay of the DOPA content using alumina 
columns at pH 8.4 and the fluorimetric procedure as previously described 
for the urine samples. The method as described achieved an excellent 
separation of DOPA and dopamine with a 94. 62 .!. 4. 30 % recovery o'f 
dopamine and a 78.67 .!. 4.6 i. recovery of DOPA as determined from known 
mixtures of the two substances (see Table 3). 
I 
' I 
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TABLE 3 
Percent recovery of DOPAa and dopamine from mixtures in 10% trichloroacetic acid 
Dopamine DOPA 
Added<rg) Found(/l"g) Percent Added ( f'- g) Found(?- g) Percent 
Recovered Recovered 
4 3.83 95.75 4 3.05 76.25 
4 4.17 104.25 4 3.14 78.50 
4 3.63 90.75 4 3.25 81.25 
4 3.95 98.75 6 4.13 68.83 
4 3.65 91.25 6 4.61 76.83 
4 3.57 89.25 6 4.87 81.17 
4 3.69 92.25 2oh 16.87 84.35 
4 3.91 97.75 2oh 16.30 81. 50 
4 3. 77 94.25 20h 15.48 77.40 
0 0 0 2oh 15.65 78.25 
0 0 0 2oh 16.70 83.50 
0 0 - 0 20h 15.25 76.25 
4 3. 71 92.75 0 0 0 
4 3.89 97.25 0 0 0 
4 3.65 91.25 0 0 0 
Mean recovery + standard deviation: Dopamine = 94.62 ~ 4.30 % DOPA= 78.67 ± 4.16 % 
a dihydroxyphenylalanine 
b an aliquot one-fifth the volume of the combined washings and effluent from the dowex 
column was assayed for DOPA content. 
.i:--
w 
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C. RESULTS 
All of the results of the various phases of this study, which include 
the values from the control and experimental rat study on the relation-
ship of urinary dopamine levels to renal hypertension and the statistical 
evaluation of these results; the results from the assay of the plasma 
obtained upon sacrifice of the hypertensive rats surviving the twenty-
week study; the results from the assay of the left ischemic kidneys from 
a group of hypertensive rats; the urinary and blood dopamine levels from 
the study in dogs; and the results obtained when d,1-DOPA was infused 
into cats with and without functional kidney tissue, are presented in 
this section . 
1. Data for the Control Group of Rats in the Urinary Dopamine Study are 
presented in TABLES 4 - 14. Each entry in these tables represents 
the results obtained from a pooled sample comprised of two animals • 
.. 
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TABLE 4 
Control Group (week one). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure rg11 )< g/24h pg/kg/24h 
mm H 
130 420 4.20 12.28 
/ 
140 178 2.31 7.86 
130 453 6.34 18.43 
135 320 4.96 14.21 
123 250 4.87 13.16 
120 380 3.42 9.83 
115 440 5.28 15.00 
125 600 6.30 17.40 
113 540 3.78 11.32 
Mean .:t. standard deviation 
125.7 + 8.97 397.9 + 133.6 4.61 + l.37 13.28 + 3.41 
a control values prior to any operative procedures 
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TABLE 5 
Control Group (week two). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood 
Pressure 
mm H 
115 
128 
120 
110 
120 
118 
120 
100 
116 
Dopamine 
pgll 
163 
237 
597 
440 
400 
514 
437 
323 
353 
Mean ! standard deviation 
115.7 ! 15.3 384.9 ! 134 
Dopamine 
}'g/24h 
5.22 
4.38 
6.87 
8.58 
7.60 
4.11 
10.49 
5.81 
7.94 
6.78 ! 2.10 
a control values prior to any operative procedures 
Dopamine 
_µg/kg/24h 
11. 25 
11.46 
15.10 
20.57 
16.89 
9.34 
24.11 
13.83 
17.30 
15.54 ! 4.75 
T 
' 
--. 
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TABLE 6 
Control Group (week four). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressqre (paired means) in male rats.a 
Blood 
Pressure 
mm H 
120 
125 
123 
120 
110 
108 
130 
105 
115 
Dopamine 
JA-gl l 
290 
186 
347 
253 
267 
254 
373 
120 
343 
Mean ~ standard deviation 
117.5 + 8.59 270.3 + 80.9 
Dopamine 
j'--8/24h 
9.57 
6.42 
6.25 
3.41 
5.87 
6.22 
10.44 
4.02 
7.20 
6.60 + 2.28 
a one week following right renal nephrectomy 
Dopamine 
jl-g/kg/ 24h 
20.19 
13.78 
13.21 
7.41 
12.36 
13.40 
21. 79 
8.20 
15.25 
13.95 + 4.76 
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TABLE 7 
Control Group (week six). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood 
Pressure 
mm H 
115 
130 
113 
115 
120 
123 
115 
120 
110 
Dopamine 
)A-g/l 
213 
233 
340 
320 
350 
177 
113 
303 
414 
Mean ± standard deviation 
117.9 ± 6.05 274 ± 95.8 
Dopamine 
pg/24h 
7.24 
5.83 
7.82 
3.84 
8.75 
4.51 
2. 77 
9.09 
7.45 
6.37 + 2.24 
a 
one week following left renal artery manipulation 
Dopamine 
fl g/kg/24h 
14.51 
11. 75 
15.83 
7.22 
17. 71 
8. 18 
5.53 
17.58 
13.45 
12.42 + 4.53 
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TABLE 8 
Control Group (week eight). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure ~g/l rs/24h ~g/kg/24h 
mm H 
118 276 6.21 11.52 
110 260 7.14 12.53 
105 296 9.03 15.28 
123 331 . 8.11 15.24 
125 251 6.78 11. 87 
120 318 5. 72 9.48 
110 298 8.34 14.30 
120 402 7.63 13.43 
110 338 7.43 12.70 
Mean .:!:. standard deviation 
115.7 :!:. 7.02 307.8 + 46.4 7. 38 .! l. 04 12.91 + l.89 
-
a three weeks following left renal artery manipulation 
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TABLE 9 
Control Group (week ten). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood 
Pressure 
mm H 
117 
130 
115 
120 
110 
110 
120 
113 
125 
Dopamine 
f-g/l 
175 
314 
262 
385 
318 
196 
304 
466 
372 
Mean ~ standard deviation 
117.8 ± 6.75 310.2 ~ 91.8 
Dopamine 
j<-S/24h 
5.15 
10.37 
4. 72 
7.13 
8.76 
5.89 
8.21 
6.76 
9.11 
7. 34 ± 1. 91 
a five weeks following left renal artery manipulation 
Dopamine 
f«-Slkg/24h 
9.35 
17.51 
7.89 
13.06 
14.29 
9.88 
14.11 
11. 76 
15.16 
12.56 + 3.10 
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TABLE 10 
Control Group (week twelve). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure f-Sll rs/24h rs/kg/24h 
mm H 
125 257 8.22 14.12 
130 332 9.13 14.54 
123 458 6.41 9.97 
118 324 7.95 13.68 
110 445 10.24 15.68 
115 210 5.79 9. 12 
125 336 6.21 10.02 
110 394 7.89 13.30 
125 389 10.88 17.24 
Mean .:!:. standard deviation 
120.1+7.19 349.4 + 81. 9 8.08 + 1. 8 13.07 + 2.79 
a seven weeks following left renal artery manipulation 
/ 
-.. 
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TABLE 11 
Control Group (week fourteen). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood 
Pressure 
mm H 
135 
123 
125 
118 
115 
110 
105 
130 
125 
Dopamine 
f'-g/l 
435 
321 
166 
371 
617 
378 
374 
336 
327 
Mean ~ standard deviation 
120.7 ± 9.58 369.4 + 118.5 
Dopamine 
f'--g/ 24h 
6.31 
8.82 
4. 97 
10.21 
15.13 
6.99 
7.11 
8.23 
9.17 
8.55 + 2.94 
a nine weeks following left renal artery manipulation 
Dopamine 
_µ-g/kg/24h 
9.55 
/ 
13.12 
7.15 
14. 77 
21.19 
9.55 
10.20 
11. 38 
14.06 
12.33 + 4.12 
..,. , 
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TABLE 12 
Control Group (week sixteen). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure f--g!l ,µ.g/24h f-g/kg/24h 
mm H 
95 397 · 9,13 13.50 
130 399 10. 78 15.69 
117 410 6.97 9.79 
135 319 9.41 13.09 
110 316 6.48 8.91 
115 403 13. 29 17.64 
125 368 11.03 15.27 
110 263 7.24 9.88 
130 323 5.98 8.64 
Mean .:_ standard deviation 
118. 5 ± 12. 7 355.3 ± 51.8 8.92 ± 2.46 12.49 ± 3.31 
a 
eleven weeks following left renal artery manipula.tion 
~ .. 
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TABLE 13 
Control Group (week eighteen). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood 
Pressure 
mm H 
125 
120 
130 
135 
110 
123 
120 
115 
130 
Dopamine 
}'-g/ l 
400 
417 
322 
366 
560 
704 
470 
229 
300 
Mean ~ standard deviation 
123.l ± 7.89 418.7 ± 144.3 
Dopamine 
fL gl 24h 
9.21 
11.47 
10.29 
6.77 
14.0l 
10. 21 
8.23 
6.31 
9.01 
9.50 ± 2.37 
a thirteen weeks following left renal artery manipulation 
Dopamine 
JA-g/kg/ 24h 
12.68 
15.29 
13.48 
9.04 
17.57 
13.41 
10.46 
8.62 
11. 36 
12.43 ± 2.91 
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TABLE 14 
Control Group (week twenty). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure rs/l rs/24h /lg/kg/ 24h 
mm H 
135 412 5.97 7.67 
/ 
125 413 13.23 16.51 
123 595 16.37 19.81 
117 266 6.53 8.17 
130 623 11. 21 13.29 
115 314 7.23 9.07 
130 321 9.15 10.92 
120 213 6. 71 8.48 
125 305 8.23 9.66 
Mean ~ standard deviation 
124.4 ± 6.53 384.7 ± 142.l 9.40 + 3.54 11.51 + 4.21 
a fifteen weeks following left renal artery manipulation 
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2. Data for the Experimental Group of Rats in the Urinary Dopamine 
Study are presented in TABLES 15 - 25. Each entry in these 
tables represents the results obtained from a pooled sample 
comprised of two animals . 
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TABLE 15 
Experimental Group (week one). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure f'-g/l l'g/24h r g/kg/24h 
mm H 
115 294 8.82 22.16 
120 270 4.86 15.43 
120 282 4.94 14.57 
113 365 8.58 25.61 
140 487 6.82 16.24 
130 200 5.50 21. 74 
115 274 8.50 25.52 
120 229 5.50 18.09 
135 295 8.40 21.82 
135 337 6.40 16.33 
125 320 ' 7.04 18.57 
120 307 5.53 15.36 
120 652 8.48 20.82 
110 
115 350 5.60 15.38 
118 250 7.50 21.55 
108 337 5.90 16.34 
123 347 9. 72 26.41 
105 383 7.66 13.30 
110 473 8.04 15.00 
115 300 - 10~· 5 21.52 
120 313 8.45 15.0l 
105 373 6. 71 11.39 
103 460 8.51 15.70 
110 400 10.00 19.01 
118 493 10.85 20.43 
110 363 10.16 18.47 
Mean .:!:_ standard deviation 
117. 7 .±. 9.37 352.+ 97.8 7.29 + 2.21 18.53 + 3.97 
a control values prior to any operative procedures 
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LE 16 
,Je rimen ta 1 G 1 eek two) tionship of urinary dopamine levels 
( pai red sample1 rte rial j pressure (paired means) in male rats.a 
Bl ood Dopa Dopamine Dopamine 
P &.· . s sure fig ! I µ g/24h f'-g/kg/24h 
;,,111 Hg 
110 424 9.54 17.73 
466 7.92 14.45 
120 199 4.29 8.46 
110 438 6.35 12.40 
125 624 12.17 21.02 
115 325 7.48 14.38 
120 382 8.59 16.61 
120 390 7.02 13.98 
120 345 7.60 15.17 
120 410 8.61 16.40 
110 387 6.97 12.38 
95 
133 327 7.52 12.99 
110 457 10. 28 18. 97 
123 413 8.26 14.59 
110 337 6.74 12.76 
110 347 7.46 13.23 
115 
115 320 5.04 11. 56 
110 390 4.68 9. 79 
115 31 7 3.80 8.08 
120 240 4.92 11. 55 
125 347 4.51 9.84 
120 277 4.43 9.42 
125 353 5.12 12.86 
115 477 5.96 13.42 
115 200 3.60 7.83 
Mean .:!:. standard deviation 
117.0 ± 7.91 367.7 _~(1. 5 6.75 + 2.16 13.19 + 3.34 
a 
control values prior to any operative procedures 
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TABLE 17 
Experimental Group (week four). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure f'- g/ l f' g/24h ~ g/kg/24h 
mm H 
105 187 2.99 5.67 
110 246 4.67 8.28 
120 287 4.02 7.96 
123 263 7. 10 12.33 
108 323 6.94 13.17 
110 257 3.98 7. 71 
103 157 3.69 6.38 
118 190 3.04 6.31 
115 383 8.81 17.41 
115 243 7.65 15.84 
120 157 4.95 10.51 
135 210 6.09 11.69 
105 180 5.94 11. 81 
130 267 8.54 17.18 
108 163 4.73 10.35 
113 233 6.29 12.14 
120 210 7.56 15.52 
123 303 11. 82 23.17 
115 167 5.51 11.43 
110 163 7.01 14.13 
123 206 6.18 13.26 
135 146 5.62 12.95 
103 303 8.79 19 .15 
120 200 4.80 9.66 
113 214 6.85 15.46 
128 207 8.69 18.65 
120 207 8.07 17.54 
Mean .:!:. standard deviation 
116.6 ±. 9.03 224.9 ± 58.5 6.31 + 2.07 12.80 + 4.39 
a one week following right renal nephrectomy 
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TABLE 19 
Experimental Group (week eight). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure f'-g/l .f'g/24h f'g/kg/24h 
mm H 
155 186 6.14 11.41 
150 274 9.32 17.10 
163 214 7.49 12.98 
163 254 7.24 . 12.64 
135 160 5.76 10.59 
173 90 5.76 9.23 
205 166 10.37 14.65 
150 103 6.39 9.86 
173 170 7.39 16.42 
168 180 8.46 13.22 
190 100 6.15 10.57 
183 146 6.64 11.37 
175 153 7.65 12.77 
145 555 7.22 12.73 
180 142 6.74 11. 74 
Mean :!:. standard deviation 
167.2 :!:. 18.5 192.9 :!:. 112. 8 7.25 + 1.31 12.48 + 2.24 
a three weeks following left renal artery constriction 
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TABLE 20 
Experimental Group (week ten). Relationship of urinary dopamine levels 
(paired samples) to arterial blood pressure (paired means) in male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure f-g/l f' g/ 24h rgtkg/24h 
mm H 
163 185 8.68 12.43 
173 207 10.35 17.49 
205 235 8.21 13.22 
173 345 8.46 16.24 
168 168 10. 91 18.77 
175 166 7.47 12.40 
163 136 6.48 10.57 
200 213 4. 91 6.86 
120 291 9.47 15.62 
180 148 7.75 12.95 
135 190 6.75 13.47 
190 266 7.84 13.17 
Mean .:t, standard deviation 
170.4 ± 24.3 212.5 ± 62.2 8.11 + 1.67 13.60 + 3.18 
a five weeks following left renal artery constriction 
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TABLE 21 
Experimental Group (week twelve). Relationship of urinary dopamine 
levels (paired samples) to arterial blood pressure (paired means) in 
male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure ?g/l f'-&I 24h f'g/kg/ 24h 
mm H 
163 223 12.69 18.65 
163 114 7.10 10. 51 
173 181 8.50 13.18 
155 129 3.81 6.67 
205 171 9.39 14.65 
173 145 6.20 9.42 
\t ' 150 221 8.61 13.26 
205 103 4.96 7.83 
180 . 103 5.81 9.23 
150 172 10.66 14.23 
135 292 16. 71 10.54 
Mean .:t, standard deviation 
168.3 ± 22.l 168.5 ± 59.0 7.68 ± 2.60 11.65 + 3.50 
a seven weeks following left renal artery constriction 
' 
-
TABLE 22 
Experimental Group (week fourteen). Relationship of urinary dopamine 
levels (paired samples) to arterial blood pressure (paired means) in 
male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure y.g/l ,µ.g/24h J-<81kg/24h 
mm H 
173 206 10.84 15.17 
173 252 15.61 22.16 
150 373 17.91 25.61 
150 137 5.35 7.61 
175 403 9.27 13.26 
135 144 9.68 14.23 
180 489 ll.24 13.98 
163 214 8.02 13.50 
205 89 6.19 8.97 
Mean :.t. standard deviation 
167.l ± 20.5 256.3 ± 136.2 10.46 + 4.11 14.94 + 5. 72 
a nine weeks following left renal artery constriction 
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TABLE 23 
Experimental Group (week sixteen). Relationship of urinary dopamine 
levels (paired samples) to arterial blood pressure (paired means) in 
male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure f<&/l )A-g/24h f'-g/kg/ 24h 
mm H 
170 287 10. 62 12.21 
180 207 11.80 15.55 
190 307 7.06 7.83 
190 283 6.51 8.75 
163 200 14.00 21.12 
200 130 7.15 8.97 
135 140 11.90 15.16 
180 429 9.86 12.80 
Mean 2:_ standard deviation 
176.0 ±. 20.3 247.9 ±. 98.96 9.86 + 2.73 12.80 + 4.45 
a 
eleven weeks following left renal artery constriction 
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TABLE 24 
Experimental Group (week eighteen). Relationship of urinary dopamine 
levels (paired samples) to arterial blood pressure (paired means) in 
male rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure fl .SI l I" g/24h I' g/kg/24h 
mm H 
168 143 9 .15 11. 10 
180 223 9.81 10.51 
175 357 12.49 14.13 
200 254 ,22. 10 27.35 
200 163 7.33 9.07 
120 160 7.44 9.23 
155 143 6.15 8.93 
175 326 9.62 13.14 
Mean .:!:. standard deviation 
66 
171.6 + 25.79 221. l + 84.4 10. 51 + 5.07 12.93 + 6.13 
a 
thirteen weeks following left renal artery constriction 
TABLE 25 
Experimental Group (week twenty). Relationship of urinary dopamine 
levels (paired samples) to arterial blood (paired means) in male 
rats.a 
Blood Dopamine Dopamine Dopamine 
Pressure ft g/l f" g/24h fi&/kg/24h 
mm H 
173 204 12.67 13.69 
150 224 10.66 12.26 
163 163 8.81 9.86 
135 371 13. 72 16.29 
173 391 11.33 15.64 
173 178 11. 55 13.07 
200 142 6.87 7.83 
Mean .:!:. standard deviation 
166.7 :t. 20.6 239.0 :t. 100.73 10.80 :t. 2.32 12.63 + 
a 
fifteen weeks following left renal artery constriction 
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3. A Statistical Evaluation of the Results Obtained from the Study on 
the Relationship of Urinary Dopamine Levels in Arterial Blood 
Pressure is presented in TABLES 26 and 27. 
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Comparisons of the means of the control and experimental groups using 
"student's" t distribution.a The calculated /T/ is followed by the 
tabulated t (in parentheses) at the 0.05 confidence level and corresponding 
degrees of freedom.b 
Week mm Hg ;igll f'g/24h )-'g/kg/24h 
1 2.240(2.032)* 1.102(2.035) 3.404(2.035)** 3.536(2.035)** 
2 0.332(2.032) 0.426(2.037) 0.036(2.037) 1.614(2.037) 
4C 0.262(2.032) 1.825(2.032) 0.355(2.032) 0.667(2.032) 
6d 6.181(2.060)*** 0.062(2.060) 3.269(2.060)** 2.967(2.060)** 
8 7.952(2.074)*** 2.884(2.074)** 0.253(2.074) 0.482(2.074) 
10 6.275(2.093)*** 2.911(2.093)** 0.985(2.093) 0.750(2.093) 
12 6.247(2.101)*** 5.734(2.101)*** 0.392(2.101) 1.212(2.101) 
14 6.148(2.120)*** 1.877(2.120) 1.134(2.120) 1.109(2.120) 
16 7.089(2.131)*** 2.846(2.131)* 0.747(2.131) 0.164(2.131) 
18 5.388(2.131)*** 1.047(2.131) 0.537(2.131) 0.219(2.131) 
20 5.863(2.145)*** 2.287(2.145)* 0.903(2.145) 0.594(2.145) 
a /T/ calculated according to Snedecor, 1956 
nin2 Cn1 + n2 - 2) 
(nl + n2) l:"x2 
b t = IT/ t rejects Ho: 1 - 2 = 0 indicating a significant difference between the control and experimental means 
* signifies a difference at the 0.05 level or less 
** signifies a difference at the 0.01 level or less 
*** signifies a difference at the 0.001 level or less 
c week following right renal nephrectomy in both experimental and control 
groups 
d week following left renal artery constriction in the experimental group; 
left renal artery manipulation in the control group 
TABLE 27 
Regression coefficients and correlation coefficients with confidence intervals and tests of the hypotheses 
for the rat data of the control and experimental groups from week 6 through week 20. 
Relationship Investigated 
Blood Pressure on Dopamine f'g/l 
Blood Pressure on Dopamine }'g/~4h 
Blood Pressure on Dopamine ,ug/kg/24h 
Dopamine p g/kg/24h on Weight in Grams 
Blood Pressure on Dopaminef'g/l 
Blood Pressure on Dopamine !'-g/24h 
Blood Pressure on Dopamine ,ug/kg/24h 
Dopamine .f'g/kg/24h on Weight in Grams 
Regression Coefficienta 
b 
CONTROL GROUP 
0.005(-0.013 to 0.023) 
0.253(-0.535 to 1.041) 
-0.082(-0.672 to 0.508) 
-0.002(-0.10 to 0.006) 
EXPERIMENTAL GROUP 
-0.040(-0.086 to 0.006) 
-0.868(-2.330 to 0.594) 
-0.943(-1.919 to 0.033) 
Correlation Coefficienta 
r 
0.062(-0.149 to 0.268) 
0.076(-0.303 to 0.156) 
-0.033(-0.262 to 0.199) 
-0.072(-0.299 to 0.160) 
-0.181(-0.376 to 0.029) 
-0.126(-0.326 to 0.085) 
-0.203(-0.391 to 0.011) 
-0.006(-0.014 to -0.002) -0.164(-0.358 to 0.049) 
t b 
cal 
0.522 
0.639 
0.276 
0.602 
1. 705 
1.179 
1. 922 
1.544 
a All calculation concerned with the regression coefficients, correlation coefficients and tests of 
hypotheses were carried out according to Snedecor, 1956. 
b Since t al does not exceed t 05 CN-2) in any instance the hypotheses: Ho:~= 0 and Ho:p = 0 are not 
rejectea. 
to5<N-2) 
1.994 
1.994 
1. 994 
1. 994 
1. 987 
1. 987 
1. 987 
1. 987 
-..J 
0 
4. Analysis of the Plasma from Hypertensive Rats Sacrificed at the 
End of the Twentieth Week. 
Assay of the individual plasmas obtained from the 14 hyper-
tensive rats which survived the 20-week study failed to demonstrate 
the presence of dopamine in any of the samples regardless of the 
manner in which the plasma was treated prior to its subsequent 
R passage through Dowex resin. 
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5. The Results Obtained from the Assay of the Ischemic Left Kidneys 
of Hypertensive Rats for Dopamine Content are presented in TABLE 28. 
TABLE 28 
Influence of renal hypertension of eight weeks duration on kidney 
dopamine content in male rats.a 
Initial Blood Pressureb Terminal Blood Pressure Dopamine Contentc 
Left Kidney (µ_g/gm) mm Hg mm Hg 
85 120 0 
110 160 0 
95 150 0 
100 120 0 
90 140 0 
80 140 0 
95 110 0 
95 105 0 
105 125 0 
100 125 0 
100 130 0 
115 145 0 
Dopamine content of the pooled blood from the above animals (80 ml) =O 
a 
The rats were subjected to a simultaneous right renal nephrectomy and 
left renal artery compression. 
b Both initial and terminal blood pressure was determined under ether 
anesthesia. 
c The blank values slightly exceeded the standard determinations in all 
assays. 
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6. , The Data for the Study of Urinary and Blood Dopamine Levels in 
I 
Control and Renal Hypertensive Dogs are presented in TABLE 29. 
< 
... 
TABLE 29 
Relationship of urinary dopamine and blood dopamine levels to arterial blood pressure in control 
and renal hypertensive dogs 
Week of Experiment 
Subject 1 2 4a 6b 7 8 9 10 
Male:Control 
Blood Pressure(rnmHg) 150 160 160 155 160 160 165 160 
Urinary Dopamine()'g/24h) 1342 497 1220 406 105 318 346 
Blood Dopamine(/'g/20 ml) 
-
0.13 0 . 07 0.13 0.17 0.07 0.17 0.20 
Male:Unilateral Neehrectomy 
Blood Pressure(mmHg) 160 170 165 155 160 170 150 165 
Urinary Dopamine( fl g/24h) 518 246 215 199 373 - 414 105 
Blood Dopamine( f'g[20ml) - 0.10 0.13 0.17 - 0 . 07 0.13 0.23 
Female:Hyeertensive 
Blood Pressure(mmHg) 140 150 150 
-
200 210 195 205 
Urinary Dopamine(f"g/24h) 271 231 333 - 278 320 209 366 
Blood Dopamine()'g/20ml) - 0.07 0.17 0.10 0 . 10 0.17 0 . 13 0.13 
Male:Hyeertensive 
Blood Pressure(mmHg) 175 160 170 - 180 200 210 215 
Urinary Dopamine( ,µg/24h) 247 290 311 
- 317 343 352 308 
Blood Dopamine(fg/20ml) 
-
0.10 0.10 0.13 0 . 07 0.07 0.17 0.20 
a first week following right renal nephrectomy in latter three subjects 
b first week following left renal artery constriction in the hypertensive subjects -...J 
lJ1 
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7. The Data Obtained from the Intravenous Infusion of d,l-DOPA in 
Cats are presented in TABLES 30 - 32. 
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TABLE 30 
Levels of dopamine and DOPA in various tissues of the untreated cat 
Cat No. Heart Liver Spleen Kidney 
( µ:g/gm) ( µg/gm) ( µg/gm) ( pg/gm) 
DOPAMINE 
1 0.18 0.16 0.31 0.07 
2 0.18 o.oo o.oo o.oo 
3 0.07 0.01 o.oos 0.02 
4 0.009 0.02 o.oo 0.009 
Average 0.11 o.os 0.08 0.02 
DOPA 
1 0.18 0.12 0.23 0.27 
2 o.oo o.oo o.oo o.oo 
3 o.oo 0.008 0.03 0.02 
4 0.01 0.01 0.03 0.05 
Average o.os 0.03 0.07 0.08 
' 
.J'ABLE 31 
Tissue levels of dopamine and DOPA in various tissues of the cat following intravenous infusion of 
50 mg/kg d,1-DOPA in cats with left kidney function. 
Cat No. Heart Liver Spleen Kidney Renal Blood (;<-g/l) 
(pg/gm) (pg/gm) ( _µg/gm) ()Ag/gm) Arterial-! Venous-! Arterial-2 Venous-2 
(10 minute samples) (one hour samples) 
DOPAMINE 
l l.91 2.6 3.30 7 . 22 74 106 74 60 
2 0.44 3.96 2.62 24.78 16 134 30 180 
3 - l.07 0.83 4.78 30 - 30 30 
4 0.40 0.56 o.24a 4.40 
-
106 30 30 
Average 0.92 - 2.05 2.25 10.29 40 115 41 75 
DOPA 
l 23.62 8.40 13.75 111. 55 22,296 16,560 4,966 3,980 
2 25.38 11.20 23.90 98.76 15,960 27,600 5,300 4,846 
3 28.60 18.70 48.24 59.02 2,984 9,142 1,320 1,306 
4 43.04 13.06 53.34 104.42 3,370 1,044 2,926 850 
Average 30.16 12.84 34.81 93.44 11, 152 13,586 3,628 2,745 
a Some of this sample was lost during handling and the value is not included in the average. 
-...J 
CX> 
TABLE 32 
Tissue levels of dopamine and DOPA in various tissues of the cat 
following intravenous infusion of 50 mg/kg d,1-DOPA in cats without 
kidney function 
Cat No. Heart 
( Jlg/gm) 
' 
1 1.54 
2 0.98 
3 0.80 
4 0.70 
Average 1.00 
1 : 35.43 
2 31.02 
3 32.24 
4 22 . 42 
Average 30.28 
Liver 
( µg/gm) 
, 
DOPAMINE 
1. 22 
4.48 
2.43 
2.75 
2. 72 
10.65 
18.84 
12.58 
14. 10 
14.04 
Spleen 
( µ.g/gm) 
2.08 
2.10 
3.60 
2.11 
2.47 
20.87 
16.48 
15.32 
18.10 
17.69 
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IV. DISCUSSION 
The data from the major portion of the study, dealing with the 
relationship of urinary dopamine levels to arterial hypertension in renal 
hypertensive rats are presented in Tables 4 through 25. It is immediately 
apparent (Figure 5) that the method used to induce hypertension (Goldblatt 
et al., 1934; Dury, 1938) was successful. The mean blood pressure values 
of the control group varied within a rather narrow range of from 115.7 
mm Hg (Table 5) to 125.7 mm Hg (Table 4), while those of the experimental 
group ranged from a low of 116.6 mm Hg (Table 17) prior to left renal 
artery constriction to a maximum of 176 mm Hg, 11 weeks following con-
striction (Table 23). 
The mean blood pressure of the control group was highest the first 
week and differed significantly (. Ol<p<. 05) from the experimental group 
for the same week. However, the mean blood pressure of the control group 
dropped the second week and then showed a tendency to rise slowly through-
out the duration of the 20-week study, never exceeding the first week's 
average. Individual variation within the control group, ignoring time as 
a possible factor, ranged from 95 mm Hg to 140 mm Hg. 
The mean of the experimental group showed a sharp increase in blood 
pressure one week following left renal artery constriction (Table 18), and 
the group means remained significantly elevated above those of the controls 
for the duration of the study (p< .001). Although the mean blood pressure 
continued to rise subsequent to renal artery constriction, the magnitude 
of the rise was offset by deaths which occurred within this group as a 
consequence of the severity of hypertension and its resultant complica-
tions. While 36 rats survived the first week subsequent tp renal-artery 
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Fig. 5. Mean blood pressures and standard deviations (mm Hg) for the 
experimental and cont~ol groups for week l through 20. 
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constriction, only 14 animals survived to the conclusion of the 20-week 
study. Individual variation within the experimental group following renal-
artery constriction, ranged from 120 mm Hg to 205 mm Hg, indicating that 
not all of the animals developed arterial hypertension. 
Urinary dopamine levels, expressed as micrograms per liter, remained 
relatively constant for the control group; the group means varied between 
' 
270 and 418 pg/l (Figure 6). Individual variation ranged from 113 to 
623 pg/l. Dopamine concentration decreased in the control group the 
fourth week of the experiment (one week following right nephrectomy) and 
then progressively rose to reach a mean level, comparable to those obtained 
initially, about the twelfth week of the experiment. 
The group means of the experimental group varied between 168 and 367 
pg/l, while individual variation ranged between 89 and 652 pg/l. A 
similar decrease in dopamine concentration was seen in this group following 
right-renal nephrectomy (Figure 6). However, in the case of the experi-
mental group rather than a tendency to rise, a tendency was noted for the 
dopamine concentration to decrease further. Comparisons between the group 
means of the control and experimental animals showed the urinary dopamine 
concentration to be significantly lower in the experimental animals for the 
eighth ( .01 >P > .001), tenth ( .01 > p > .001), twelfth (p< .001), sixteenth 
(p <.05) and twentieth (p~.05) weeks of the study (Table 26). 
The regression and correlation coefficients for the dependency of 
blood pressure on dopamine concentration (pg/l) from the sixth through the 
twentieth week of the study are shown in Table 27. The regression and 
correlation coefficients of the control group are b=0.005 and r=0.062 
respectively, while those of the experimental group are b= -0.040 and 
r= -0.181 respectively. However, none of these values are statistically 
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Fig. 6. Mean urinary dopamine levels and standard deviations (pg/l) for 
the experimental and control groups for week 1 through 20. 
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significant and the hypothesis Ho:~=O and Ho:f =O cannot be rejected; 
this implies that no relationship exists between dopamine concentration and 
arterial blood pressure. 
DeFanti (1961) reported finding a highly significant positive regres-
sion coefficient for dependency of blood pressure on logarithm dopamine 
concentration in hypertensive rats, for dopamine concentrations ranging 
from 500 to 1000 pg/l. The above results are not in agreement with these 
findings. Possible explanations for the discrepancy lie in the different 
methods of statistical analysis and assay methods used in the two studies. 
DeFanti worked with six groups of experimental animals comprised of from 
one to six animals each which survived left renal artery compression. The 
mean values for blood pressure and dopamine concentration from these six 
groups were averaged to obtain pooled means and standard deviations of 
dopamine concentration and blood pressure for each week of the study. 
Apparently, the contribution of each group to the pooled mean was weighed 
equally despite variation in the number of animals comprising each group. 
These pooled means, from the first through the twelfth week following left 
renal artery compression, were then utilized in the regression analysis. 
In the present study, the values from 88 paired assays were utilized for 
the analysis. 
Based upon the regression analysis statistics, DeFanti concluded that, 
11 72% of the variations occurring in blood pressure could be explained on 
the basis of the linear regression of blood pressure on dopamine." No 
direct . comparisons were made between the dopamine levels of the control 
group and the experimental group. Dopamine levels were reported for the 
control group for the first, second, third, fourth, fifth, sixth, and 
eighth weeks following right nephrectomy. Non-statistical comparison of 
85 
the dopamine levels of the control group with those of the experimental 
groups for these same weeks showed the dopamine levels in the control 
group to exceed those of the experimental group in 17 out of a possible 33 
instances, In addition, the pooled means of the hypertensive animals were 
below that of the pooled control mean (obtained prior to left renal artery 
constriction) from these same animals for the first five weeks following 
left renal artery compression. However, during this five-week period the 
blood pressure had risen from a control value of 122+4.3 mm Hg to 173 
+11.2 mm Hg. During this major rise in blood pressure, the dopamine levels 
remained below the pre-operational control value. Under these circum-
stances it is difficult to accept the dependancy of blood pressure on 
urinary dopamine levels. 
Probably a more important contribution to the differences seen in 
the two studies was made by differences in methodology rather than 
differences in statistical evaluation of the data. While DeFanti used 
Dowex Sodium 50W-X8 to extract dopamine from the urine, the present study 
used alumina. In addition, changes were made in the assay procedure itself, 
particularly in the blank. These changes were necessitated by the dis-
covery, early in the present study, that Dowex resin was extracting a 
substance with native fluorescence from the urine of hypertensive rats 
I 
and that the blank (Carlsson and Waldeck, 1958) by quenching this f luores-
cence was resulting in erroneously high urinary dopamine levels. By using 
alumina and changing the order of addition of reagents in the blank, this 
I 
difficulty was circumvented in the present study. The explanation seems 
compatible with the results; for while alumina extracted 82.43 +11.73% of 
variable amounts of dopamine added to urine (Table 2) compared with 
74.52 +10.99% reported by DeFanti, the range of dopamine values was lower 
86 
in the present study (89-652 fg/l) than reported by DeFanti (97-1569 pg/l). 
Other investigators have encountered difficulties with the dopamine assay, 
and various modifications can be found in the literature (Drujan et al., 
1959; McGeer and McGeer, 1962; Brodie et al., 1962; Carlsson and Lindqvist, 
1962; Anton and Sayre, 1964). The strong cation exchange resins (e.g. 
Dowex 50W-X8) have been reported to give off fluorescent material 
(Haggendal, 1962; Ibid., 1966); and absorption onto alumina at pH 8.6 seems 
superior and more specific, particularly for urine (Anton and Sayre, 1962; 
Ibid., 1964; Haggendal, 1966). 
(Tables 4 through 25 also present urinary dopamine levels as total 
micrograms excreted per 24 hours (pg/24 hr) and micrograms per killogram 
per 24 hours (pg/kg/24 hr). Since a change in the volume of urine produced 
in a 24-hour period could have a significant influence on dopamine levels 
when reported as concentration, it was thought necessary to compare the 
total micrograms excreted per 24 hours between the control and experi-
mental groups. The results of the two groups differed significantly only 
for the first and sixth weeks of the experiment ( .001 < p < .Ol). The 
discrepancy for the first week could possibly be attributed to variable 
adaptation to experimental procedure. The difference seen the sixth week 
(first week following left renal artery constriction) probably i ·s a result 
of temporary alteration of renal function or a rebound phenomenon conse-
quent to renal impairment. The excretion of dopamine (pg/24 hr) tended 
to increase (Figure 7) in both groups over the duration of the study, 
indicating a possible relationship with time (e.g. age). This possibility 
was not statistically evaluated, but is in agreement with other studies 
(Burn, 1953). The relationship between blood pressure and dopamine 
Cpg/24 hr), however, was investigated for . both groups. No relationship 
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Fig. 7. Mean urinary dopamine levels and standard deviations (pg/24h)" for 
the experimental and control groups for week 1 through 20. 
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was found to exist for either of the groups when the data from the sixth 
week on, independent of time, was subjected to a determination of the 
regression and correlation 7oefficients. The values are shown in Table 27. 
The regression coefficient (b) for the control group was 0.253 and for the 
experimental group -0.868. The correlation coefficient (r) was 0.076 for 
the control group and-0.126 for the experimental group. Although these 
values took different directions, it is important to note that they were 
not statistically significant. 
Urinary dopamine values expressed as micrograms per kilogram per 
24 hours were reported because DeFanti and DeFeo (1963) reported finding 
an increased excretion of dopamine Cpg/kg/24 hr) when plotted against 
weight (gm) for hypertensive rats, contrasted with a decrease in normo-
tensive rats. Leduc (1961) also reported a decrease in urinary dopamine 
levels Cpg/kg/24 hr) in normotensive rats as body weight increased. In 
the present study a slight tendency for dopamine levels Cpg/kg/24 hr) to 
decrease with increased weight was noted for both the experimental and 
control groups; however, neither trend proved statistically significant 
(Table 27). Also subjection of the data on dependency of blood pressure 
to dopamine levels Cpg/kg/24 hr) to a determination of the regression and 
correlation coefficients resulted in values of low magnitude which were 
not statistically significant. Comparisons between the two groups (Table 
26; Figure 7) disclosed a significant difference between the two groups 
for only the first and sixth weeks, resulting in a situation similar to 
that encountered when dopamine levels Cpg/24 hr) were compared. 
In light of the above findings, it appears that the quantity of 
dopamine excreted in the urine, expressed either as total micrograms per 
24 hours or as micrograms per killogram per 24 hours, follows a similar 
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pattern in normotensive and hypertensive rats. It also appears that the 
total quantity of dopamine excreted per 24 hours tends to increase with 
time (e.g., age), while . the dopamine levels reported as micrograms per 
killogram per 24 hours tend to remain relatively constant or display a 
slightly downward trend as body weight increases. Since dopamine levels 
expressed as micrograms per liter were significantly lower on several 
occasions in the hypertensive groups of animals, an explanation is 
necessary. The explanation would seem to be an increase in urinary 
90 
volume which occurred in the experimental group subsequent to left renal 
artery constriction. An increase in urinary output is commonly encount-
ered in renal hypertension as the kidneys lose their power to concentrate 
the urine. If this dilution factor is taken into account, as it is when 
dopamine levels are reported as micrograms excreted per 24 hours or micro-
grams excreted per killogram per 24 hours, then no consistent significant 
differences are seen to exist between the normotensive and hypertensive 
animals. The only possible conclusion is that urinary dopamine levels 
bear no relationship to the increase in blood pressure as a result of renal 
ischemia in rats. 
The urinary dopamine levels <pg/24 hr) for the study carried out in 
dogs are presented in Table 29. These values are quite variable; however, 
there are no obvious differences between the values for the hypertensive 
dogs, the control dog or the unilaterally nephrectomized control dog. 
The infusion of d,1-DOPA in cats with and without functional renal 
tissue (Tables 30, 31 and 32) was carried out to determine the role of 
the kidneys in the increased tissue levels of dopamine reported to occur 
following DOPA infusion (Wegmann, 1963) . The tissue levels of dopamine 
and DOPA found in the untreated control cats are presented in Table 30. 
' , 
The dopamine levels were low i n all the tissues examined; the mean levels 
were highest in the heart (O. ll pg/gm), next highest in the spleen (0.08 
pg/gm), next in the liver (0.05 pg/gm), and lowest in the kidney ( 0. 02· 
pg/gm). Mean DOPA levels were very low (0.08 pglg in all tissues). 
Wegmann (1963) r~ported detectable levels of dopamine in the spleen and 
kidney of untreated dogs but not in heart and liver. Anton and Sayre 
(1964) reported finding very low levels of dopamine in the tissues of the 
dog, the highest value being found in the heart (0.05 pg/gm). These same 
investigators reported the highest level of dopamine in the cat spleen 
(0.12 pg/gm) and similar levels in the heart, liver, and kidney (0.07 
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pg/gm). Both investigators failed to detect DOPA in any of these tissues. 
Following the infusion of d,1-DOPA in cats with left renal function, there 
was an increase in the dopamine content of all the tissues examined. The 
pattern of increase was the same as that obtained by Wegmann, the dopamine 
level being highest in the kidney (10.29 pg/gm) followed in order by the 
spleen (2.25 pg/gm), liver (2.05 pg/gm), and heart (0.92 pg/gm). The DOPA 
level was highest in the kidney (93.44 pg/gm), followed in order by the 
spleen (34.81 pg/gm), heart (30,16 pg/gm), and liver (12.84 pg/gm); again 
the pattern was similar to that reported by Wegmann. Blood samples taken 
during the experiment showed that some synthesis of dopamine was taking 
place in the kidney. An arterial blood sample taken midway through the 
infusion period from the abdominal aorta near the origin of the lef t renal 
artery showed a dopamine content of 40 pg/l , while a venous blood sample 
obtained from the left renal vein via th~ ovarian vein for the same time 
showed a dopamine content of 115 pg/l . Blood samples obtained in a similar 
manner one hour after initiation of the infusion (40 minutes after con-
clusion of the infusion) showed an arterial dopamine level of 41 pg/l and 
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a venous level of 75 pg/l. As might be expected, the blood levels of DOPA 
were ve,ry high. The values presented in the same order as above were 
arterial: 11,152 pg/l; venous, 13,586 pg/l; arterial, 3.628; venous, 
2.745 pg/l. The high value obtained for the first venous sample probably 
represents a slight contamination of the sample with blood from the abdom-
inal vein through which DOPA was being infused. Similar tissue levels of 
dopamine were obtained in the heart (1.00 pg/gm), liver (2.72pg/gm), and 
spleen (2.47 pg/gm) when d,1-DOPA was infused into cats without kidney 
function . This finding would imply that the kidney contributes very 
little to the increased dopamine levels seen in these tissues. Dopamine 
synthesis either takes place in situ within the heart, liver, and spleen 
or as suggested by Wegmann, possibly the liver contributes to the tissue 
levels in the other two organs. Circumstantial evidence might support 
this. The liver is known to possess a high degree of DOPA decarboxylase 
activity (Blaschke, 1939) and yet the dopamine level in this organ following 
DOPA infusion is surprisingly low. However, the DOPA content of the liver 
is also relatively low following DOPA infusion. This could indicate a 
rapid turnover of DOPA in the liver with subsequent release of dopamine 
into the circulation. 
None of the results from this investigation implicate dopamine in the 
renal hypertensive process. No relationship was established between 
urinary dopamine levels and arterial blood pressure in hypertensive rats 
or dogs. In addition, dopamine could not be demonstrated in the blood of 
hypertensive rats or dogs or in the renal tissue of hypertensive rats. 
Doubt was also cast upon the role of the kidney in contributing to 
an increase in tissue dopamine levels following the infusion of d,1-DOPA. 
Evidence was presented that the kidney does decarboxylate DOPA, but 
93 
evidence was also presented that this had little influence on dopamine 
levels in heart, liver and spleen. 
A question raised by the investigation is the nature of the native 
fluorescence found present in Dowex 50W-X8 extracts of hypertensive rat 
urines. High blanks were also encountered in the assay of the ischemic 
kidneys. Is it possible that the substances are one and the same and may 
be involved in the hypertensive process? Further investigation along this 
line might proye profitable. 
I 
I 
V. SUMMARY AND CONCLUSIONS 
Arterial hypertension was induced in male rats of the Wistar strain 
and in mongrel dogs by right renal nephrectomy and left renal artery 
constriction for the purpose of studying the relationship of urinary, 
blood, and kidney dopamine levels to the resulting increase in blood 
pressure. In the rats a significant increase in blood pressure was 
obtained the first week following left renal artery constriction, and the 
pressure remained significantly elevated above that of a sham-operated 
control group for the duration of the study. The highest mean blood 
pressure for the hypertensive group (176 mm Hg) was obtained on the 
eleventh week following renal artery constriction. Individual blood 
pressures ranged as high as 205 mm Hg. Similar results were obtained in 
the hypertensive dogs. 
A new method was developed for the fluorimetric assay of urinary 
dopamine by modification of existing methods. Alumina was used to extract 
dopamine, and this eliminated certain difficulties which were initially 
encountered when Dowex sodium 50W-X8 was used. Recovery of known quanti-
ties of dopamine added to urine samples averaged 82.43 +11.73%. Dopamine 
was extracted from blood and tissues principally by homogenization in 10% 
I 
trichloroacetic acid followed by passage through alumina. A method was 
also devised to separate DOPA from dopamine contained in the same tissue 
extract. This was accomplished by first passing a trichloroacetic acid 
extract through sodium Dowex to extract dopamine, then through alumina to 
extract DOPA. Excellent separation and recoveries were obtained. 
Comparisons of urinary dopamine levels were carried out between the 
control and hypertensive groups of rats. Dopamine concentration <pg/l) 
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was significantly lower on several occasions in the hypertensive group. 
However, dopamine levels reported as micrograms per 24 hours or micrograms 
per kilogram per 24 hours differed significantly on only two occasions--
once during the pre-operational control period and again on the first week 
following left renal artery constriction. A diuresis was observed in the 
hypertensive rats, which could explain the apparent decrease in dopamine 
concentration <pg/l). Dopamine levels (pg/24 hr) showed a tendency to 
increase in both the control and experimental groups during the period of 
the study while dopamine levels (pg/k/24 hr) remained relatively constant 
and displayed only a slight tendency to decrease. Regression and correla-
tion coefficients were determined in both groups of rats for the following 
relationships: blood pressure on urina·ry dopamine (pg/l), blood pressure 
on urinary dopamine (pg/24 hr), blood pressure on urinary dopamine 
(pg/kg/24 hr), and dopamine (pg/kg/24 hr) on weight (gm). No statistically 
significant relationships were discovered. Dopamine could not be detected 
in the blood or kidneys of hypertensive rats or in the blood of hyperten-
sive dogs. 
A relationship between dopamine and the hypertensive process was not 
established in the present study, and it is doubtful that dopamine plays 
a role in the elevation of blood pressure which takes place following 
right nephrectomy and left renal artery constriction in the rat or dog. 
d,l-DOPA was infused into cats with and without functional renal 
tissue to determine the contribution of the kidneys to tissue levels of 
dopamine. Tissue dopamine levels were elevated to a similar degree in 
liver, spleen, and heart in both instances; however, renal arterio-venous 
differences indicated that some decarboxylation of DOPA to dopamine did 
take place in the kidney. The similar tissue levels were probably a 
result of saturation of uptake sites in the tissues, and it was suggested 
that the liver may have contributed to the tissue levels in the heart and 
spleen of the totally nephrectomized cats. 
I 
I 
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